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ABSTRACT 
 
 
Introduction  
Paediatric low grade brain tumours present diagnostic and prognostic challenges, 
providing a need for better non-invasive imaging characterization. 1H Magnetic 
Resonance Spectroscopy (MRS) holds important biologic information, and in this 
work its value in the diagnosis and prognostication of an extensive bi-centre cohort 
of low-grade gliomas is investigated.  
Methods 
Single voxel MRS was performed routinely in children with brain tumours as part of 
the clinical imaging (1.5T or 3.0T) prior to any treatment at the Birmingham 
Children’s Hospital and Queen’s Medical Centre (1st September 2003 - 31st March 
2009). Clinical, imaging, MRS and histopathological data was collected on this 
patient cohort, up to 31 May 2010. Histopathological features were semi-quantified 
and correlated with MRS metabolites. In vitro 1H Nuclear Magnetic Resonance 
spectroscopy (NMR) of cell extracts and whole cell samples from three pilocytic 
astrocytoma cell lines was performed. Two cases were studied with Magnetic 
Resonance Spectroscopic Imaging (MRSI). Texture analysis of T1- and T2- 
weighted MR images was performed for the diagnosis of paediatric posterior fossa 
brain tumours.   
Results 
MRS detects differences between subgroups of low grade brain tumours in 
children and between tumours of the same histology. High myo-inositol and 
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glycerophosphocholine and low phosphocholine have been found to be markers of 
good prognosis. Histological correlates for MRS metabolites have been identified 
and paediatric pilocytic astrocytoma cell lines (‘typical’, metastatic and recurrence) 
have been discriminated by in vitro 1H NMR. The value of MRSI in answering 
specific clinical questions has been demonstrated. Texture analysis of MR images 
has been used to diagnose paediatric posterior fossa brain tumours with high 
accuracy. 
Conclusion 
This is the first study to the best of our knowledge which investigates an extensive 
cohort of paediatric low grade gliomas with MRS, collecting clinical, imaging and 
histopathological data from 2 centers and 5 scanners. Promising results have been 
reported by our group and others in the field, and advanced MR techniques now 
have a significant role in the study of these tumours.  
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CHAPTER 1 
 
INTRODUCTION 
 
Paediatric low grade brain tumours present diagnostic, prognostic and treatment 
monitoring challenges, providing a need for better non-invasive imaging 
techniques. They are relatively uncommon, with approximately 350 cases 
diagnosed each year in the UK, and less than 60 patients treated in any one of the 
22 UK Children’s Study Group (UKCCSG) centers per year(1).   1H magnetic 
resonance spectroscopy (MRS) has shown promise in answering some of the 
management questions in previous studies of brain tumours in adults and children.  
 
1.1. Paediatric Brain Tumours 
 
Brain and spinal cord  tumours are the commonest solid tumours in children (2, 3), 
representing 20% of all childhood cancers (4). In a study of 147 children <15 years, 
the annual incidence of central nervous system tumours was 26.5 per million 
children <15 years (3). However, central nervous system (CNS) tumours comprise 
many histologic entities with widely varying characteristics. Astrocytomas, 
medulloblastomas and ependymomas are the three commonest types of tumour, in 
order of incidence (3, 5). In a study of 340 children with primary CNS tumours up to 
17 years of age, pilocytic astrocytomas were the most frequently encountered 
(23.5%), followed by medulloblastomas (16.3%) and ependymomas (10.1%), with 
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astrocytomas comprising 47.3% of all tumours (5). In a meta-analysis of Rickert 
and Paulus’ data and data from another 15 worldwide studies on brain tumours in 
children, astrocytomas comprised 37.6% of all tumours, medulloblastomas 17.7%, 
ependymomas 9.9%, craniopharyngiomas 7.3% and germ cell tumours 4.4% (5). 
However, there are differences in the relative frequencies of paediatric brain 
tumours across ages, with medulloblastomas for example being the most common 
tumour at 6-11 years of age and high-grade astrocytomas, ependymomas and 
medulloblastomas being more frequent in the first 3 years of life (5).   Differences 
are detected between Western countries and Japan and between ethnic groups in 
the US in total incidence and relative frequencies of certain histologic  types, 
suggesting the contribution of genetic predisposition in the aetiology of CNS 
tumours (4).  
 
Furthermore, there is an obvious difference in relative frequencies of the various 
tumour types between children and adults, which suggests a different aetiology (4, 
6). High grade gliomas are the commonest primary brain tumours in adults, but 
only comprise 5% of those in children (6). High grade astrocytomas are the most 
common tumour between 15 and 17 years of age (5). Pilocytic astrocytomas and 
low-grade fibrillary astrocytomas are more common in children. Ependymomas are 
significantly more prevalent in children, especially infants and young children, and 
high grade gliomas originating in the brain stem are detected mainly in children (6).  
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The prevalence of CNS tumours in boys was found to be higher in all age groups 
throughout childhood and adolescence (5). There is also a difference in primary 
location; infratentorial tumours are more common in children, especially >1 year, 
whereas primary brain tumours in adults are usually supratentorial (3, 6). In 
children, infratentorial tumours are more prevalent at the ages of 3-11, with initially 
more supratentorial tumours at ages 0-2, as well as after 11 years of age(5).   
 
Brain tumours also cause the highest number of deaths among paediatric cancer 
(7) and the combination of the tumour and its treatment commonly causes 
significant morbidity, in terms of physical deficits, neuropsychological and 
neuroendocrine effects (8). 75% of brain tumours in children are found in the 
midline and therefore often cause occlusive hydrocephalus (5). In the study by 
Stevens et al., survival was reported at 51% at 5 years for all diagnoses, but 
ranged from 13% in unbiopsied brain stem gliomas to 100% in juvenile 
astrocytomas (3).  
 
1.2. Paediatric Low Grade Gliomas 
 
Low grade gliomas are a clinically defined group of tumours, used to describe 
WHO grade I and II tumours of glial origin, excluding ependymomas (9). Some 
glioneuronal tumours are included in this group and are treated under the same 
protocol (9). Ependymomas are not included, even though of glial cell origin, as 
they form a clinically separate entity with a different treatment approach.   
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Low grade gliomas are the most common brain tumours in children(10). Although 
commonly grouped together for the purposes of treatment, low grade gliomas are a 
diverse group in terms of histopathology (11). Most low grade gliomas in children 
are grade 1 pilocytic astrocytomas (PA), which comprise 23.5% of all brain tumours 
in children,  but some are grade 2 diffuse astrocytomas (5% of all paediatric brain 
tumours are fibrillary astrocytomas) and many other rarer tumour types are seen 
(5). Pilocytic astrocytomas are particularly common between 3 and 14 years of 
age, ranging from 21.8% in 9-11 years of age to 32.8% in 3-5 years of age (5).  
Furthermore, low grade glioneuronal tumours such as gangliogliomas are often 
grouped with the pure gliomas in treatment protocols. Low grade gliomas may 
occur throughout the brain and prognosis depends greatly on the site. Cerebellar 
PAs have an excellent prognosis and are often curable by complete surgical 
resection (11, 12). Conversely, optic pathway tumours which account for 2-5% of 
all brain tumours in childhood are much more challenging to treat (11, 13). Up to 
70% of optic pathway tumours are associated with neurofibromatosis type 1 
(NF1)(14), and approximately 15% of patients with NF1 can have an optic pathway 
glioma (6).  
 
Although overall survival (OS) rates are generally high for low grade gliomas in 
children, progression-free survival (PFS) is much lower. In a study by Fisher et al., 
5 and 10 year (from initial surgery) OS for low grade astrocytomas was 87% and 
83%, and PFS was 55% and 42% (15). A significant number of children progress 
after incomplete tumour resection or biopsy, and patients who have not had a 
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complete surgical resection at diagnosis often receive adjuvant treatment with 
chemotherapy and/or radiotherapy (9). Response to adjuvant treatment is variable 
and differs between tumour types, accurate diagnosis and improved tumour 
characterization is therefore important. 
  
 A substantial proportion of low grade gliomas are not biopsied or biopsy is limited 
with its inherent risks of sampling error (11, 16, 17). Currently, clinical findings 
together with conventional magnetic resonance imaging (MRI) appearances are 
used for non-invasive diagnosis, which provides information on the position, size, 
shape and structure of tumours. However, they present multiple management 
challenges, as they can have similar clinical presentations, magnetic resonance 
imaging (MRI) characteristics, and even histopathological features when biopsied, 
whilst simultaneously having very different responses to treatment. Treatment of 
low grade gliomas in the UK follows the SIOP-LGG   2004  protocol, and can 
include surgery, chemotherapy or radiotherapy or a combination of these (9). In 
addition, the clinical symptoms and signs and the magnetic resonance imaging 
(MRI) characteristics of these tumours are not always straightforward to interpret. A 
tumour may appear to be getting smaller on MRI but the patient’s vision may be 
deteriorating and vice versa. Tumour measurements have been the major focus in 
assessing tumour response, and there have been multiple guidelines, such as 
World Health Organization (WHO) in 1979, Response Evaluation Criteria in Solid 
Tumours (RECIST) in 2000, the revised RECIST 1.1 in 2009 (18-20), and the 
Response Assessment in Neuro-Oncology (RANO) working group criteria (21). 
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The RANO criteria recognize that contrast enhancement (addressed in the 
Macdonald Criteria (22)) is non-specific and may not always reflect tumour 
response, and account for the non-enhancing component of brain tumours (21). 
These have been applied in diffuse low-grade gliomas (23) and are currently being 
developed for paediatric brain tumours (24). However, there are significant 
limitations in measuring tumour size, such as lack of distinct borders and irregular 
shape tumours (20). Although decreasing tumour volume is considered a sign of 
response, the tumour may contain dead cells and there may be a delay in volume 
change during treatment (25). There is therefore increasing interest in using 
functional imaging to assess tumour response, as this can give information on 
metabolic, hypoxic, proliferative and receptor status of lesions. However, these 
modalities need to be validated if they are to be incorporated in future RECIST 
versions (26).  
 
These tumours therefore present significant challenges for non-invasive diagnosis 
but also an opportunity for improved non-invasive characterization where novel 
biomarkers of clinical behavior can be identified. New magnetic resonance 
techniques are becoming available which can give information on tumour 
properties providing insight into the biology of these lesions and improving their 
non-invasive assessment (27, 28).  One such technique, 1H Magnetic Resonance 
Spectroscopy (MRS) provides information on chemical composition and has been 
shown to be a valuable non-invasive tool for the diagnosis and grading of brain 
tumours both in adults (29)  and children (16, 30, 31). It  can  easily be combined 
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with current MR imaging protocols making it an attractive adjunct to current 
assessments (27).  
 
1.3. Treatment of Paediatric Low Grade Gliomas 
 
In the UK, low grade gliomas (histologically or radiologically confirmed, WHO grade 
I or II, tumours of glial origin, some mixed glioneuronal tumours) in any part of the 
central nervous system in children and adolescents up to the age of 16 years are 
treated with the SIOP-LGG 2004 protocol (9). Ependymomas and diffuse intrinsic 
tumours of the pons are excluded, although grade 2 pontine gliomas in NF1 
patients are eligible for the study (9). This protocol separates patients into groups 
according to tumour location and NF1 status, and then by the extent of primary 
resection, presence of severe neurologic symptoms and tumour progression. 
Different histologic entities are included in different locations, making the treatment 
recommendation very complex; this is why largely individualized treatment is 
allowed within the protocol. The protocol suggests the following: patients who have 
complete tumour resection, or incomplete resection or clinical diagnosis without 
symptoms or progression should be observed; definite indications for treatment 
after incomplete resection, non-resectable relapse or progression of an 
unresectable tumour should be treated with non-surgical therapy; children ≥8 years 
of age should receive primary radiotherapy and may also receive chemotherapy 
under specific conditions; interstitial radiotherapy indication in not restricted 
according to age; younger children should receive primary chemotherapy (duration 
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of 18 months); children with NF1 should be treated with chemotherapy at all ages; 
children without NF1 should be randomized to receive standard induction 
chemotherapy with vincristine and carboplatin or intensified induction with 
vincristine, carboplatin and etoposide; consolidation therapy is the same for all 
patients (vincristine and carboplatin). There is a high frequency of carboplatin 
hypersensitivity reactions (42% in a study of 105 patients from 10 Canadian 
centers (32)). Alternative chemotherapy in SIOP-LGG 2004 (for patients not 
affected by NF1) includes alternating Cisplatin/Vincristine and 
Cyclophosphamide/Vincristine (9).  However, cisplatin  is nephrotoxic and 
neurotoxic (9).  
 
Surgery should be considered first at diagnosis or relapse, and complete resection 
is possible in up to 90% in some locations (9).  Chemotherapy has been shown in 
several large, national studies to be effective against surgically unresectable, 
progressive or symptomatic low grade gliomas (9). It decreases tumour volume, 
prolongs progression-free survival and delays radiotherapy. However, the role of 
chemotherapy in long-term outcome, and its effect on improving the clinical and 
neurological function need further investigation (9).  
 
1.4. Imaging of Paediatric Brain Tumours 
 
Paediatric brain tumours are routinely imaged with Computed Tomography 
Imaging (CT) and/or Magnetic Resonance Imaging (MRI) (33). Most children have 
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an MRI of the brain before surgery, as it is better at determining tumour extent and 
spread compared to CT (33), but as CT is widely available it is often the first 
imaging modality used when a child presents with symptoms relating to a possible 
brain tumour (7). CT can be used to more easily assess the presence of 
calcifications which helps in the characterization of craniopharyngiomas and 
teratomas. MR is better at detecting the presence of blood (34).  Functional 
imaging has also been gaining increasing interest and use, including Magnetic 
Resonance Spectroscopy (MRS) and Magnetic Resonance Spectroscopic Imaging 
(MRSI), perfusion MR, diffusion weighted imaging (DWI) and diffusion tensor 
imaging (DTI) and cortical activation mapping (33). Functional imaging modalities 
have different applications and are at different stages of development and review 
regarding clinical application in paediatric brain tumours. Imaging is involved in 
characterization (detection, spatial localization, extent, grading, histology), staging, 
prognostication, treatment planning and assessment of treatment response, as well 
as surveillance of patients and evaluation of long-term tumour and treatment 
effects. (33) 
 
When a mass is detected on imaging, the distinction between intra- and extra-
parenchymal lesions needs to be made. If it is intraparenchymal, its nature needs 
to be defined; infection, large plaques of demyelination and infarction can mimic 
the appearance of neoplasms (34). Standard sequences used in MR evaluation of 
paediatric brain tumours include sagittal T1-weighted images, followed by axial T2-
weighted spin echo or fast spin echo and fluid attenuated inversion recovery 
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(FLAIR) images. Additional coronal or axial images can be performed through the 
tumour, and post-contrast images are performed in the optimal planes based on 
the pre-contrast images (34).  
MRI has excellent sensitivity and specificity in the detection of paediatric brain 
tumours, and is slightly better than CT in this regard, and can also detect local 
tumour extent very accurately in non-infiltrative lesions. However, the extent of 
infiltration is often not determined when lesions are infiltrative or have significant 
surrounding oedema, which cannot be discriminated from tumour. It is possible to 
have normal appearing areas on MRI which are infiltrated by tumour.  Grading of 
lesions on MRI features is often possible using their mass effect, presence of 
peritumoural oedema, sharpness of tumour margins, signal intensity patterns and 
patterns of enhancement. However, it is possible to have malignant tumours 
appearing very benign on conventional MRI (33). 
 
Pre-operative diagnosis is often possible with MRI, when tumours have 
characteristic imaging features, such as infiltrative pontine gliomas and optic 
pathway gliomas in patients with Neurofibromatosis type I (NF1) (33). However, 
optic pathway tumours can be very infiltrative and difficult to discriminate from the 
T2 bright foci of vacuolation within myelin sheaths which are characteristic of 
NF1(33). Furthermore, cortical lesions such as gangliogliomas, dysembryoplastic 
neuroepithelial tumours (DNET) and pilocytic astrocytomas can have suggestive 
imaging features, but also demonstrate overlap with other histologies such as 
ependymomas, pleomorphic xanthoastrocytomas and oligodendrogliomas (33, 35). 
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Regarding staging (33), MRI is used to assess the central nervous system and 
detect dissemination of disease. In most tumour types, subarachnoid metastatic 
disease is a negative prognostic indicator. Spinal MRI is routinely used with CSF 
cytology to diagnose leptomeningeal disease, as spinal MRI does not diagnose all 
patients with leptomeningeal disease and has false positives and false negatives. 
Subarachnoid metastatic deposits are detected on gadolinium T1 weighted images 
as enhancing nodules or carpet-like covering of the surface of the brain and spinal 
cord or in the lumbar thecal sac below the conus. Furthermore, gadolinium-
enhanced T1-weighted MR images used to detect subarachnoid metastatic 
deposits can lack sensitivity when the primary tumour does not enhance, as these 
deposits may also not enhance. FLAIR images can identify menigneal disease in 
the cranium that may not be detected by gadolinium-enhanced T1-weighted 
images, but this also has limitations due to CSF pulsatility and the use 
anaesthetics and oxygen in some children, and cannot be used for the spine (33). 
 
Tumour volume measurements performed on MRI have various limitations, but are 
currently the only validated imaging marker which is predictive of outcome. In 
assessing the response to therapy, MRI also has limitations in discriminating 
tumour recurrence from post-radiation necrosis (33). 
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1.4.1. Tumour Location and Typical MR Imaging Characteristics of Paediatric 
Brain Tumours  
 
The diagnosis of paediatric brain tumours involves several factors which need to 
be considered in obtaining an accurate differential. These are the patient’s age, 
tumour site, intra-axial versus extra-axial location, lesion cellularity, enhancement 
pattern, and amount of perilesional oedema (7).  
 
1.4.1.1. Posterior Fossa Tumours 
The most common posterior fossa tumours in children are medulloblastomas, 
pilocytic astrocytomas and ependymomas (7). Although «typical» imaging 
appearances can be identified for posterior fossa tumours, it is important to note 
that there is significant overlap in these, and conventional imaging is not always 
definitive. Medulloblastomas usually arise from the roof of the fourth ventricle and 
the inferior medullary velum, and have hypointense T2 signal due to their 
increased cellularity (7). Ependymomas usually arise from the floor of the fourth 
ventricle and extend through the foramen of Luschka or Magendie, and can have 
varied T2 signal according to their histological subtype (7). Pilocytic astrocytomas 
are usually cystic with a mural nodule, the solid part being hyperintense on T2-
weighted images, but can also be more solid (7). Ependymomas may present with 
similar T2 signal intensity to medulloblastomas, and medulloblastomas can have 
similar growth patterns to ependymomas (7). Also, cystic/necrotic 
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medulloblastomas may have imaging features overlapping with posterior fossa 
pilocytic astrocytomas (7). 
 
1.4.1.2. Suprasellar Tumours 
The main suprasellar tumours in children are optic pathway/hypothalamic gliomas, 
craniopharyngiomas and germ cell tumours. These tumours can have 
characteristic appearances, but can also present as mixed cystic and solid lesions. 
Craniopharyngiomas are discriminated by their predominantly cystic nature and rim 
clacification on CT or gradient echo imaging. Germ cell tumours have hypointense 
solid portions on T2-weighted imaging whereas optic pathway/hypothalamic 
gliomas (usually pilocytic astrocytomas) have hyperintense solid portions (7). 
 
1.4.1.3. Supratentorial Tumours  
Primitive neuroectodermal tumours, pilocytic astrocytomas, ependymomas and 
atypical teratoid rhabdoid tumours can be found supratentorially. Fibrillary (diffuse) 
astrocytomas, low-grade astrocytomas, anaplastic astrocytomas and glioblastoma 
multiformis can present supra- or infratentorially. Pleomorphic astrocytomas and 
subependymal giant cell astrocytomas usually present only supratentorially. 
Ganglion cell tumours including gangliogliomas and dysembryoplastic 
neuroepithelial tumours often present supratentorially (7). Pilocytic astrocytomas 
are often cystic, appear bright on T2-weighted MRI and enhance after contrast 
administration (7). Grade 2 and 3 astrocytomas are mostly non-enhancing, and 
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show significant variation in imaging characteristics within same grade tumours 
and within the same tumours (7).  
 
1.4.1.4. Brain Stem Tumours 
Brain stem tumours encompass significantly varying lesions in terms of 
appearance, therapy and prognosis; they form at least four separate major 
categories: medullary tumours, pontine tumours, mesencephalic tumours and 
tumours associated with NF1. These can be further subclassified into focal and 
diffuse tumours (7, 34). The most common lesion is diffuse intrinsic brain stem 
glioma or diffuse pontine gliomas, which can be low-grade at presentation, but is 
inoperable, resistant to treatment and has the worst prognosis of all tumours in 
paediatric neuro-oncology (7). Other brainstem lesions have a better prognosis; 
astroyctomas can be found in the tectum (7). 
 
1.5.  Magnetic Resonance Spectroscopy (MRS) Applications 
1.5.1. Applications in Various Disorders 
 
MRS is a technique which can be combined with magnetic resonance imaging to 
measure the concentration of a multitude of metabolites and lipids, and allows the 
biochemical characterization of tissue in vivo. 1H MRS has been used extensively 
in recent years to investigate various disorders involving the brain as well as other 
organs, in adults and children. In the study of malignant lesions, it has been used 
particularly in brain, prostate and breast tumours. Prostate cancer is often difficult 
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to detect by routine ultrasound, CT and MRI (36) and biopsy samples only are not 
accurate for determining the Gleason score (37); Proton Magnetic Resonance 
Spectroscopic Imaging (MRSI) with MRI can provide information on the location 
and extent of cancer in the peripheral zone of the prostate, detect changes in 
citrate, creatine and choline which predict the presence of tumour, and achieve 
high sensitivity and specificity (36, 38), as well as assess aggressiveness of the 
tumour (39, 40). Furthermore, MRSI has been used to detect local recurrence after 
external-beam radiotherapy of the prostate (36, 41, 42). Breast cancer is 
diagnosed mainly by conventional film-screen mammography, but this method has 
a low specificity for detection of abnormal breast tissue (36). 1H MRS has shown 
increased choline in malignant lesions (43, 44), and the addition of MRS to MRI 
has been shown to improve sensitivity, specificity and accuracy in distinguishing 
malignant from benign breast lesions (45, 46). Furthermore, MRS has been used 
to monitor response to treatment after neoadjuvant chemotherapy in locally 
advanced breast cancer (47, 48). It is worth noting that there is a consistent 
increase in choline in vivo and in vitro in tumours relative to surrounding healthy 
tissue, and a consistent decrease in choline in lesions responding to treatment 
compared to those which are not (36).  
 
 In vivo MRS has been used to study many disorders of the CNS system or 
systemic disorders with CNS involvement. Burtscher et al. reviewed proton MR 
sepctroscopy in clinical routine, and described that N-acetyl-aspartate (NAA) has 
been shown to be decreased in temporal lobe epilepsy, cerebral space occupying 
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lesions, multiple sclerosis (MS), Alzheimer’s disease (AD) and other types of 
dementia and hypoxia (49). Other metabolites vary in these disorders as well, such 
as early choline (Cho) and lactate (Lac) increases and early transient creatine (Cr) 
decrease in MS; increased myo-inositol (mIns) in AD and increased Cho in multi-
infarct dementia, and accumulation of lactate and increase in glutamate+glutamine 
(Glx) in hypoxia (from asphyxia, stroke, trauma etc.) (49).   
 
 In vivo MRS has been used to study metabolic disorders such as mitochondrial 
disorders, phenylketonuria and chronic hepatic encephalopathy (49); 
neuropsychiatric disorders, such as schizophrenia, bipolar disorder and autism 
(50), and various types of non-CNS tumours, such as musculoskeletal tumours 
(51) and non-Hodgkin’s lymphoma (52). In vivo 31P NMR spectroscopy has been 
used to provide predictors of treatment response to chemotherapy in human 
musculoskeletal tumours (51). In non-Hodgkin’s lymphoma, pre-treatment 31P MRS 
characteristics differed between low and high grade lymphoma, and metabolite 
changes occurred with treatment before changes in tumour size (52).  
 
1.5.2. MRS Applications in Adult Brain Tumours 
 
One of the main disorders studied by 1H MRS is brain tumours, and extensive 
research has been published on adult patients or cohorts of adults and children 
together. One such project was INTERPRET (53), a multi-centre project which 
developed a decision-support system (DSS) to aid radiologists in the diagnosis and 
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grading of brain tumours. Most tumour spectra had elevated choline relative to 
creatine, in contrast to normal brain spectra. The DSS classified 89% of the cases 
in an independent test set of meningiomas, low-grade gliomas and high-grade 
malignant tumours successfully (53). This project was expanded in the 
HEALTHAGENTS work, which included a distributed multi-centre agent 
architecture, an in-vivo classification method with negotiation, a web-based user 
interface and additional cases (54).  eTUMOUR built on INTERPRET and used  
classifiers developed from previous data at different hospitals with the same 
acquisition protocol  to evaluate predictive models with unseen cases, achieving 
high discrimination accuracies (55). Other applications of 1H MRS in brain tumours 
included tumour biopsy guidance (56), tumour grading (lower mIns/Cr ratios in 
anaplastic astrocytomas and GBMs compared to low-grade astorcytomas at short 
TE(57), correlation between choline and Ki-67 in homogeneous gliomas at long 
TE(58)), detection of necrosis, and assessment of treatment (36, 59, 60).   
 
1.5.3. MRS in Paediatric Brain Tumours 
1.5.3.1. Diagnosis and Characterization 
 
There have been increasing numbers of studies in the paediatric population, 
although still limited compared to published work on adult brain tumours. There is 
now a growing body of literature on specific metabolic changes in paediatric brain 
tumours, which can be used as a basis for further larger multicentre studies, 
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needed to increase the numbers of patients, study specific tumour sub-types, and 
validate the use of 1H MRS clinically.  
   
A preliminary Chemical Shift Imaging (CSI) and haemodynamic MR imaging study 
of brain tumours in children and young adults (61), suggested that active tumour 
may be discriminated from normal tissue and necrosis. Normal tissue 
demonstrated characteristic peaks from N-acetyl-aspartate (NAA), choline-
containing compounds (Cho) and total creatine (tCr). Biopsy-proven tumours had 
prominent Cho, reduced NAA, variable tCr and/or lactate or lipids. Radiation 
treatment caused lower metabolite peaks. Tissue necrosis had no Cho, NAA, or 
tCr. Another study of CSI in paediatric brain tumours (10 months-24 years) found 
significantly higher Cho and lipids and/or lactate (L) and lower tCr and NAA in 
tumours compared to normal brain in what was termed as «active tumours» (Cho 
and NAA also significant in «inactive tumours») (62). Similarly, Peet et al. (27) 
demonstrated significantly lower NAA/Cho and Cr/Cho in all types of tumours 
studied with short TE SVS compared to normal brain tissue, as well as the 
presence of  lipids and macromolecules in most tumours, which are low in normal 
brain tissue (27). Furthermore, myoinositol (Inos)/choline was significantly lower in 
untreated tumours compared to normal brain, was high in diffuse pontine gliomas 
and low in medulloblastomas and supratentorial primitive neuroectodermal 
tumours(27). Glutamate/Glutamine (Glut)/ Cho was high in grade 1 astrocytomas 
and unbiopsied optic gliomas and low in diffuse pontine gliomas(27). Diffuse 
pontine gliomas also had significant metabolite differences from other gliomas in 
20 
 
the brain stem (27).  Panigrahy et al. (63) used short echo time SVS to discriminate 
between  individual tumour types from all other tumours and between pairs of 
tumours types, and found many significant differences; taurine was significantly 
higher in medulloblastomas compared to all other tumours, creatine was 
significantly lower in pilocytic astrocytomas and ependymomas and anaplastic 
ependymomas demonstrated low NAA compared to all others. Decision support 
systems with an interactive clinical user interface have also been produced for the 
characterization of childhood brain tumours with MRS, and provide a flexible 
method for  tumour classification by clinicians (64).  
 
A short echo time SVS study by Peet et al. (65) showed that children with 
metastatic medulloblastomas had significantly smaller primary tumours, higher 
choline levels and choline/lipids ratio and lower mobile lipid (at 1.3+0.9 ppm) and 
lactate levels,  than children with localized disease (65). Total choline also had a 
significant positive correlation with Ki67(65).  Tzika et al. (16) has demonstrated a 
positive correlation between Cho and relative cerebral blood volume (rCBV) and an 
inverse correlation between Cho and apparent tissue water diffusion coefficient 
(ADC). Cho and lipids were not correlated, and lipids were positively correlated 
with ADC. Total creatine was significantly positively correlated with NAA as well as 
Cho (16). MRSI has also been investigated (28) regarding its relationship to 
gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) enhancement in 
paediatric brain tumours, and choline-containing compounds and lipids did not 
correlate with percent enhancement. High choline indicating tumour was seen in 
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tumour regions as well as outside the enhancing tumour beds. Also, contrast-
enhancing regions in malignant and inoperable tumours did not always have high 
choline levels. However, percent enhancement correlated positively with relative 
cerebral blood volume (rCBV) and negatively with apparent diffusion coefficients 
(ADC). rCBV, ADC and lipids were found to be significant independent predictors 
of percent enhancement.   
 
Differences in metabolite profiles have also been detected within a single histologic 
tumour type, pilocytic astrocytomas, with supratentorial tumours having 
significantly higher myoinositol and glutamate + glutamine than cerebellar tumours 
prior to treatment, but no difference on qualitative review of conventional MRI 
characteristics (66). One of the earlier studies by Lazareff et al. (67) also studied 
low grade astrocytomas in 7 children with 1H MRSI (TE= 272ms) and 
demonstrated lower normalized (to value in normal brain) NAA, creatine and 
choline (except 1 patient) and higher Cho/NAA (significant in 6 patients) in tumours 
compared to normal brain, with wide variation in Cho/NAA even within the same 
tumour (67).    
 
1.5.3.1.1. NF1 
In a study of brain lesions in children with NF1 by Wilkinson et al. (68), N-acetyl 
group resonance at 2.02ppm (NA) was found to be significantly lower in typical 
Neurofibromatosis Bright Objects (NBOs) and non-optic tract/hypothalamic 
tumour/atypical NBO compared to controls. Cho and mIns were significantly higher 
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in tumour/atypical NBO compared to typical NBO and control groups. Three of the 
glutamate+glutamine (Glx) resonances were significantly lower in tumour/atypical 
NBO compared to controls.  Gonen et al.(69) found that focal areas of signal 
intensity (FASI) in children with NF1 had significantly elevated Cho, reduced 
creatine, 2>Cho/Cr>1.3 and nearly normal NAA, and differed from tumours which 
had no NAA and Cho/Cr>2. Castillo et al.(70) studied hamartomas in NF1 patients 
(5-49 years) and found they had lower NAA/Cr than healthy volunteers, but higher 
NAA/Cr, Cr/Cho and NAA/Cho than astrocytomas. Cr/Cho and NAA/Cho in 
hamartomas was similar to healthy volunteers. However, the astrocytomas studied 
were from patients with no NF1 and included low and high grade tumours.  
 
1.5.3.1.2. Posterior fossa tumours 
A study of 17 children with posterior fossa tumours achieved discrimination 
between medulloblastoma, ependymoma, pilocytic astrocytoma and infiltrating 
gliomas using a combination of ADC values and MRS metabolites normalized 
using water  (likelihood <1x10-9). Medulloblastomas demonstrated increased 
taurine (Tau) and Cho and reduced ADC, ependymomas had significantly higher 
glutamate+glutamine (Glx) compared to all other tumours, and infiltrating gliomas 
had higher mIns compared to pilocytic astrocytomas (71). 
 
In a study of paediatric cerebellar tumours with single voxel long echo time (135 or 
270ms), Wang et al. (31) found that benign astrocytomas had lower Cr/Cho and 
NAA/Cho compared to normal brain. NAA/Cho and Lac/Cho in ependymomas and 
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astrocytomas were similar, but Cr/Cho was higher in ependymomas. Cr/Cho and 
NAA/Cho was low in most primitive neuroectodermal tumours, and most did not 
have highly elevated Lac/Cho, in many lactate being undetectable. Astrocytomas 
differed significantly on ΝΑΑ/Cho from ependymomas and primitive 
neuroectodermal tumours, and ependymomas differed marginally significantly from 
primitive neuroectodermal tumours. Astrocytomas and primitive neuroectodermal 
tumours differed significantly on Cr/Cho from ependymomas. Primitive 
neuroectodermal tumours differed significantly from ependymomas and 
astrocytomas on Lac/Cho. Discriminant analysis on ependymomas, astrocytomas 
and primitive neuroectodermal tumours using NAA/Cho and Cr/Cho yielded 
classification sensitivities of 75-91% and specificities of 84-92% (no cross-
validation). Arle et al.(72) also studied 33 children with primitive neuroectodermal 
tumours, astrocytomas and ependymomas/other tumours of the posterior fossa (30 
patients same as in study by Wang et al. (31)) with long TE SVS. Cr/NAA, 
NAA/Cho and Cr/Cho, 10 MR imaging tumour characteristics, tumour size, 
patient’s age and sex were used in a neural network and compared to predictions 
made by a neuroradiologist blind to the MRS and histopathology results. The 
neuroradiologist predicted the tumour type with 73% accuracy, and neural 
networks with different data combinations as inputs achieved accuracies of 58-
95%. The neural network with MRS data alone achieved a prediction accuracy of 
58.5%, with MR imaging characteristics + age + sex + tumour size 71.7%, with 
MRS + age + sex + tumour size 87.8% and with all data 94.6%.   
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1.5.3.2. Grading  
 
Peet et al. showed absolute mobile lipid levels detected by short TE single-voxel 
MRS in children with brain tumours to be significantly lower in non-involved brain 
compared with low-grade gliomas. They were also significantly lower in low grade 
gliomas compared with malignant brain tumours. Cho/Cr was not found to be 
significantly different between low-grade and malignant tumours (73). Choline and 
lipids discriminated between low– and high-grade paediatric brain tumours, being 
significantly higher in histologic category I than in II and III (CCG) (16), and in a 
larger study (74) Cho and lipids and/or lactate (L) were elevated in high grade 
(WHO grade III and IV) vs. low grade tumours (WHO grade I and II) and were 
found to be independent predictors of tumour grade. Normalized values of Cho+ 
0.49L maximized diagnostic accuracy (74). Furthermore, the region of the MRSI 
spectrum with the highest Cho has been shown to strongly correlate with the most 
malignant areas in the biopsy specimens (74).  
 
Glycine, a metabolite often not included in metabolite profile studies due to strong 
overlap with myoinositol and a low concentration in normal brain, has been shown 
in a study of paediatric brain tumours in vivo at short and long TE to be significantly 
higher in high-grade compared to low-grade tumours. This was also the case on 
HRMAS data, and normalized glycine concentrations from HRMAS spectra 
correlated significantly with the corresponding normalized glycine concentrations 
from short TE in vivo MRS(75).  Bluml et al. (76) have also reported mean citrate to 
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be significantly higher in aggressive WHO grade II paediatric astrocytomas 
compared to indolent grade II astrocytomas (stable disease for >2 years). 
However, anaplastic astrocytomas and glioblastomas did not show a consistent 
pattern of citrate in their spectra.    
 
1.5.3.3. Prognosis and Response to treatment 
 
Peet et al.(27) demonstrated myoinositol (Inos)/Cho to be significantly lower in 
untreated compared to treated brain tumours. Harris et al. showed that children 
with supratentorial pilocytic astrocytomas who progressed had a significantly lower 
value of myoinositol at pre-treatment short TE SVS compared to those with stable 
disease. Furthermore,  the patients who progressed had a significant decrease in 
myoinositol between the pre-treatment and first on-treatment MRS (66). These 
changes in myoinositol were detected before clinical and radiological progression 
(66).   Long TE single-voxel 1H MRS in 14 young people with hemisphere tumours 
showed NAA/Cho and Cr/Cho to be significantly lower in patients who died 
compared to those who were alive after follow-up (77).  Mobile lipids have been 
shown to be highest (short TE SVS) in children with low-grade gliomas  having 
rapid clinical progression (73).  In a study of 11 patients with low grade gliomas by 
Lazareff et al., normalized choline detected by 1H MRSI pre-treatment was 
significantly higher in  tumours that progressed compared to those which had 
stable disease (78).  
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MRSI has been used to predict progression in paediatric brain tumours, with the 
percent change in Cho/NAA being significantly higher in patients with progressive 
compared to stable outcomes, and being the most important prognostic indicator of 
tumour progression (TE=65ms). Relative tumour blood volume was also higher in 
progressing compared to stable outcomes. Normalized choline and relative tumour 
blood volume (rTBV) were significantly positively correlated and Cho/NAA and 
rTBV interacted to predict the probability of a progressing clinical outcome, both 
being independent multivariate predictors of outcome (79). Warren et al. studied 
recurrent primary brain tumours with 1H MRSI and found that patients with a 
maximum Choline/NAA ratio equal to or below the median had a significantly 
greater survival than those with ratios above the median (80). Cho and lipids 
and/or lactate have been shown to be significantly higher and total creatine (tCr) 
lower in «active tumours» (recurrent or untreated) compared to «inactive tumours» 
(treated with no signs of recurrence). tCr was shown to be the only significant 
independent multivariate predictor of tumour growth (62).  Tumour spectral 
patterns (high choline) in paediatric malignant and inoperable  brain tumours have 
been demonstrated outside the enhancing tumour beds in patients who had 
recurrence at these sites subsequently (4 patients) (28).  
 
In an MRSI study of 76 children with brain tumours at TE of 65ms, choline-
containing compounds (Cho), lipids and/or lactate (L), Cho/NAA, Cho+0.1L and 
grade were significantly lower in survivors compared to non-survivors, and 
Cho+0.1L was the only independent predictor of survival (81). A study of 1H MRSI 
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(TE=272ms) in paediatric gliomas (82) showed tumour-to-brain choline decreased 
significantly after  treatment in patients who had a decrease or stable tumour 
volume and excellent clinical condition, and this decrease remained significant 
during follow-up, whereas in the patients who progressed this ratio increased after 
treatment.  The post-treatment choline was significantly higher in the non-
responders. However, pre-treatment values of normalized choline did not differ 
significantly between non-responders and responders to therapy (82).  
 
In diffuse intrinsic pontine gliomas (DIPG), which have a very poor prognosis, high 
Cho/NAA on the initial study and increase in Cho/NAA between time points, as well 
as increases in the variance in Cho/NAA in different magnetic resonance 
spectroscopic imaging (MRSI) voxels in a tumour have been shown to be 
predictive of poorer survival (83). Another study of DIPGs by Hipp et al. (84), also 
found increased Cho/NAA at baseline imaging to be predictive of poorer survival, in 
addition to increased perfusion on DSC-MRI. At subsequent time points increased 
maximum Cho/NAA on MRSI and increased Cho/NAA on single voxel 
spectroscopy, increased perfusion and the presence of enhancement predicted 
shorter survival (84). Yamasaki et al.(85) reported high Cho/NAA and lactate 
expression to be associated with shorter overall survival (5 of 19 patients >20).  
 
MRS studies have been performed at various echo times (TE) (28, 74, 86, 87) and 
these are usually referred to as short and long echo time. Long echo time studies 
were initially preferred, as they are easier to perform and collect good quality data 
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from, however this limits the number of metabolites that can be detected, in 
particular myo-inositol and glutamate/glutamine (86). Myo-inositol has been shown 
to be a prognostic indicator in pilocytic astrocytomas (66)  and glutamate/glutamine 
have been shown to be useful in distinguishing tumours from controls in patients 
with NF1 (68). Therefore, short echo time MRS is becoming standard practice.  
 
MRS is a challenging technique in children with brain tumours as many of the 
tumours are small and close to bone or blood such as near the base of the skull, 
and it is difficult to get homogeneous magnetic fields (86). This can result in poor 
quality data, which is a major problem with MRS. In addition, most studies have 
been performed at single centers (86), as it is very difficult to get multicentre data 
which follow the same acquisition protocols, and are collected consistently, and 
collecting clinical data from multiple centers is also challenging. However, this is 
very important as it is the only way to increase the number of patients in studies 
and get more reliable and statistically meaningful results.    
 
1.6. Aims & Objectives 
 
The project described in this thesis aims to assess the ability of 1H MRS to 
contribute additional biochemical information to the non-invasive characterization 
of paediatric low grade gliomas. Diagnosis and prognostication of low-grade 
gliomas using 1H MRS will be investigated, and metabolic correlates of routinely 
assessed brain tumour histopathological features examined. In vitro 1H NMR 
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spectroscopy of different pilocytic astrocytoma cells lines will aim to detect subtle 
differences between them, investigate the origin of N-acetyl-aspartate (NAA) in 
pilocytic astrocytomas in vivo, and provide a high resolution metabolic fingerprint. 
The clinical application of Magnetic Resonance Spectroscopic Imaging (MRSI) will 
also be demonstrated using case studies. Finally, we will test another quantitative 
technique, texture analysis of MR images, for the diagnosis of posterior fossa 
paediatric brain tumours, which can serve as a test-bed for the methodology.  
 
1.7. Thesis Outline 
 
As discussed above, paediatric low grade brain tumours present diagnostic, 
prognostic and treatment monitoring challenges, providing a need for better non-
invasive imaging techniques. Furthermore, childhood brain tumours are relatively 
uncommon, with approximately 350 cases diagnosed each year in the UK, and 
less than 60 patients treated in any one of the 22 UK Children’s Study Group 
(UKCCSG) centers per year (1). MRS has shown promise in answering some of 
the management questions in previous studies of brain tumours in adults and 
children.  
 
Therefore, this thesis discusses paediatric brain tumours, their treatment and 
imaging and the applications of magnetic resonance spectroscopy in various 
disorders, particularly paediatric brain tumours (Chapter 1). The technique of 1H 
Magnetic Resonance Spectroscopy (MRS) will be described in Chapter 2. The 
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common methods employed in the collection of the in vivo 1H single voxel MRS 
data, as well as the patient cohort, will be given in Chapter 3. The investigation of 
the use of MRS in the diagnosis and prognosis of an extensive bi-centre cohort of 
low grade brain tumours will be presented in Chapters 4 and 5 respectively.  
Chapter 6 will discuss the investigation of histopathological correlates of 
metabolites detected by MRS in paediatric brain tumours. Chapter 7 describes 
some pilot work with pilocytic astrocytoma cell line in vitro NMR. 2 case studies of 
patients with magnetic resonance spectroscopic imaging (MRSI) will be discussed 
in Chapter 8, demonstrating the ability of this technique to answer specific clinical 
questions. Chapter 9 will describe collaborative work on texture analysis of 
magnetic resonance images for the diagnosis of paediatric posterior fossa 
tumours, demonstrating another quantitative characterization technique, which can 
be potentially combined with MRS. Finally, Chapter 10 will conclude the work and 
discuss future work.  
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CHAPTER 2 MAGNETIC RESONANCE SPECTROSCOPY  
 
2.1. Theory 
 
MRS allows the biochemical characterization of tissue in vivo. It measures the 
concentration of a multitude of molecules by detecting the radiowave resonance 
frequency of certain atomic nuclei (proton being the most widely measured in vivo, 
but also 13C, 31P, 19F and others) when placed in a strong magnetic field.  Nuclei 
resonate at a specific frequency, f, determined by the equation below: 
f= γB0, where γ is the gyromagnetic ratio for the nucleus and B0 is the strength of 
the external magnetic field (88). However, each nucleus in a molecule has a 
slightly different resonance frequency due to shielding from its surrounding 
electronic cloud in the structure, or its chemical environment, which alters the 
actual B0. This small change in resonance frequency is called chemical shift, and it 
enables detection of specific molecules, which can be seen as peaks at different 
positions (88). Chemical shift is measured in parts per million (ppm) relative to a 
standard because it scales with the B0 field strength; it is therefore independent of 
the magnetic field at which the acquisition takes place, and is the same in all 
human MR scanners (89). Thus, it is used instead of absolute frequency to enable 
comparisons. The peaks are seen on a graphical representation of relative 
frequency on the x-axis and intensity on the y-axis (spectrum), and the area under 
each peak is proportional to the concentration of the molecule (concentration of 
protons) (88). The signal detected by the MR spectrometer is called Free Induction 
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Decay (FID), which represents the time evolution of the signal. A spectrum shows 
the components of the signal as a function of frequency, and is produced from the 
FID by Fourier transform (FT) (90).  
 
2.2. Acquisition 
 
As with conventional MR imaging the patient lies on a bed in a space with an 
external magnetic field and additional electromagnetic fields which are repeatedly 
switched on and off. The signals from resonating protons are mapped to produce 
an image. 1H MRS is most commonly used in vivo, as protons have a high 
abundance and gyromagnetic ratio and thus provide a stronger signal in a 
reasonable time frame than MRS based on other nuclei. Three additional steps are 
needed in performing MRS. A volume of interest or voxel needs to be selected 
based on the reference images acquired, the magnetic field within this voxel needs 
to be refined (uniform) by shimming, and for 1H MRS the protons of water within 
the voxel need to be suppressed (particular frequency band suppressed) (91). 
Shimming is very important (usually done automatically) as it affects resolution and 
lineshape which have a significant impact on quantitation. A water unsuppressed 
spectrum is acquired after the water suppressed one, and is used as a 
concentration reference and for eddy current correction. 1H MRS of the brain can 
be performed with a standard volume head coil,  but to increase the signal surface 
coils or an assembly of surface coils called phased-array (most commonly used) 
can also be used (91).   
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MRS can be performed in vitro and in vivo. In in vivo MRS, data is collected from 
voxels, which are pre-defined volumes of interest, such as the site of a tumour. 
One problem with voxel location by the PRESS method is chemical shift artifacts, 
which means that the excited volume (i.e. voxel position) can depend on the 
chemical shift of individual resonances. When a volume with metabolites of 
different chemical shifts is subjected to a section-selective gradient, there is a 
displacement of the sensitive volume for each resonance (92, 93). Volumes in this 
work are usually defined on the 2ppm resonance (not consistent for all scanners), 
the advantages being that this resonance is approximately the centre of the most 
interesting signals for tumours and also minimizes the effect of contamination from 
NAA in normal brain outside the target volume.   
 
The severity of the chemical shift artifact effect depends on the excitation 
bandwidth per unit distance and the field strength of the magnet (94). For the same 
voxel size, a stronger gradient and broader excitation bandwidth reduces chemical 
shift displacement, which can be negligible at lower field strength (1.5T). 
Furthermore, it is easier to reduce the chemical shift displacement for single voxel 
spectroscopy (SVS) than magnetic resonance spectroscopic imaging (MRSI), 
since smaller excitation volumes are used and a lower demand on the excitation 
bandwidth is placed (93). PRESS sequence also results in larger chemical shift 
displacement artifact than STEAM, although lately the characteristics of the 180° 
pulses in PRESS have been greatly improved, reducing this issue (93).    
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When a single voxel is used (single voxel spectroscopy (SVS)), MR signal from 
one region of interest is measured and signals outside this area are excluded. The 
localization techniques used can select cubes, rhomboid shapes, «slices», or 
multiple boxes by applying certain sequences. The most commonly used 
sequences in 1H MRS include stimulated echo acquisition mode (STEAM) and 
point-resolved spectroscopy (PRESS). Each has certain advantages, but more 
important is consistency (91). They both aim to excite the volume of interest with a 
minimum excitation of the rest of the sample. Three slice-selective pulses along x, 
y, and z are applied in a single pulse sequence (89). STEAM uses three 90° pulses 
for the excitation, whereas PRESS uses one 90° pulse and two 180° pulses. 
PRESS (which is used for all spectra in this thesis) uses the first 90° pulse to excite 
all the magnetization in one slice; the second pulse (180°) is applied in a slice 
perpendicular to the previous slice and generates a first spin echo from a row or 
column of intersection between the two slices; the third pulse (180°) is 
perpendicular to the previous two excited slices and generates a second spin echo 
of magnetization form the intersection of all three slices (89). Additional crusher 
gradients are applied between radiofrequency (RF) pulses and before the data 
readout,  in order to suppress unwanted echo signals not arising from the final 180° 
pulse  and to dephase any FID from imperfect 180° pulses (89). PRESS has the 
advantage of faster acquisition time or acquisition from smaller voxels in the same 
time with comparable signal-to-noise (S/N) ratio. This is due to the inherent loss of 
50% of the signal in each STEAM acquisition (89). It is therefore preferred in brain 
tumour applications where S/N ratio and voxel size are important (89). However, 
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STEAM allows shorter echo times (TE), as the time between the second and third 
RF pusle (TM) does not affect the TE (89).  
 
Magnetic resonance spectroscopic imaging (MRSI) or chemical shift imaging (CSI) 
involves a grid of voxels in a plane (2D) or a volume (3D), which investigate 
specific areas of interest. Chemical shift imaging involves the simultaneous 
acquisition of multiple spectra from a slice (Fig.1) or volume in the brain and 
combines MRI and MRS features. Images of specific metabolites can be formed 
and co-registered on MR images (89, 91). Spatial localization is done by phase 
encoding in two or three directions. CSI has the obvious advantage of acquiring 
multiple spectra efficiently, covering a large area of the brain, and also allows the 
adjustment of any voxel position after the measurement is finished (grid shifting). 
However, it is more difficult to achieve a good shim and uniform water suppression 
over a large volume. Furthermore, lipid signals from the skull due to incomplete 
localization can interfere. The acquisition time is longer and patients may move 
and the data sets are bulky and difficult to analyze (89, 91).   
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Fig. 1 CSI grid and choline map co-registered on MR image in a child with a diffuse 
fibrillary astrocytoma grade II. The choline map shows a red area (blue-red=low-
high) adjacent to the main bulk of the tumour, indicating that this may represent an 
area of higher malignancy.  
 
Echo time (TE) is the time interval in which the magnetization is on the transverse 
plane and undergoes T2 decay. It is an important parameter in MRS which affects 
the metabolites which can be detected and the baseline, which is much flatter at 
long TE. 1H MRS can be performed at short echo time (TE) (<135ms, usually 20-
40ms,) or long echo time (>135ms, usually 135 or 270ms) (Fig.2). At long TE, lipid 
signals and signals from metabolites with a complex spectral pattern like glutamate 
and glutamine decay due to J-coupling and T2 relaxation effects. J-coupling is the 
splitting of resonances into multiplet components, due to an internal indirect 
interaction of two spins via the intervening electron structure of the molecule. Eddy 
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current problems are also less severe at long TE (although shielded gradients and 
post-processing address this). Long TE spectra are therefore easier to analyze, as 
good estimates of metabolite concentrations can be obtained at lower resolutions 
and signal-to-noise (S/N) ratios. Short TE enables more metabolite information to 
be obtained and gives the smallest T2 losses thus producing the best S/N ratio. It 
is therefore becoming common practice to acquire short TE spectra. However, 
short TE spectra are more complex to analyze and assign peaks, due to the 
increased and often overlapping signals (metabolites detected described under 
analysis). Another parameter which is reported in MRS sequences is the repetition 
time (TR). This is the time between each initial excitation of the magnetization in 
the multiple single scans which are acquired and averaged to improve the S/N ratio 
(89, 91, 95). 
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Fig.2 Short (TE=30) and long (TE=135) TE spectra of normal white matter. Myo-
inositol, Glutamine+Glutamate and Lipids+Macromolecules are not seen in the 
long TE spectrum, and the lactate doublet is inverted. NAA=N-acetyl-aspartate, 
Cr=Creatine, Cho=Choline, mIns=myo-inositol, Glux=glutamine+glutamate, 
ppm=parts per million 
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2.3. Post-processing  
   
Post-processing encompasses a multitude of techniques which aim to enhance the 
measured signal in MRS after acquisition. This is necessary as the quality of the 
data obtained by in vivo MRS has certain limitations, such as low S/N ratio due to 
low concentration of metabolites and limited acquisition time, poor uniformity of the 
magnetic fields which would result in unreliable quantitation of the signals and 
residual water. These techniques are usually integrated in quantification software 
and therefore done automatically (90). 
 
2.3.1. Eddy Current Correction 
Switching gradients on and off during a sequence causes respective current 
changes in the conductive parts of the MR scanner, called eddy currents. These in 
turn cause additional magnetic fields which add to the gradient field used for slice 
selection and interact with the signal. The lineshapes of peaks can be distorted as 
a result (time dependent phase shifts in the FID), impairing accurate quantitation of 
the signal. Eddy current correction involves the elimination of the time dependent 
phase shifts from the FID, usually by acquiring a water unsuppressed reference 
FID (for 1H MRS), using the same protocol so that it is subject to approximately the 
same eddy currents (90). 
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2.3.2. Water Removal 
Water suppression is performed during acquisition, as water concentration in the 
brain is several orders of magnitude higher than the concentration of other 
metabolites, and small distortions of the water peak’s tail can disturb the lower 
intensity signals. However, a residual water signal remains in the spectrum, due to 
magnetic field inhomogeneities and water’s multi-compartment nature. This can be 
removed by post-processing techniques (90). 
 
2.3.3. Signal filtering in the time domain 
Filters or windows are special functions used to enhance or suppress different 
parts of the FID to improve the quality of the signal (multiplied by the FID or other 
mathematical operations). Noise corrupts the FID and small resonances can be 
lost in it; it is caused by thermal motion of charged particles in the sample and by 
thermal motion of electrons in the coil and reception paths (major source of noise). 
The S/N ratio is used to describe the quality of the signal. Post-processing to 
reduce the noise by signal filtering is called sensitivity enhancement. Another use 
of post-acquisition filtering is resolution enhancement, which refers to the artificial 
narrowing of linewidths in the spectrum. When the acquisition finishes before the 
signal decays to the noise level because the acquisition time is too short, the signal 
is truncated, and typical oscillatory signal tails or ‘ripples’ are seen in the spectrum 
(when zero filling is performed). A third use of post-acquisition filtering is 
apodization, which refers to removal of the discontinuity at the end of the FID which 
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suppresses the ripple from the spectrum.  Only one filter is applied to the data in 
practice (90).  
  
2.3.4. Zero Filling 
The signal of the FID is sampled point by point during acquisition, using an 
analogue to digital converter. If the number of points is insufficient, the signal is 
misrepresented. The number of points is dictated by the measurement parameters, 
but they can be increased artificially after acquisition. This is done by zero filling, 
which appends zeros after the last measured point in the FID. The spectrum 
produced by Fourier transform is therefore interpolated to the total number of 
points (including the zeros). This improves digital resolution (not true resolution) 
when a longer acquisition time is not possible (e.g. acquisition of just noise if longer 
acquisition time applied), and is useful in FFT which needs the number of points to 
be a power of 2 (90). 
 
2.3.5. Phase Correction 
The initial phase of the different components of the FID is usually non-zero. Phase 
correction therefore needs to be applied to restore pure absorption and dispersion 
lineshapes. This is done by multiplying the complex spectrum by the complex 
phase factor equal to the initial phase of the FID (90). 
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2.3.6. Baseline Correction 
The baseline is the unknown background in the spectra, which causes peaks not to 
lie on a flat line with zero intensity. A distorted baseline is due to hardware 
imperfections and signal originating from the sample.  Background signals are 
usually broad signals with very short T2* values, such as macromolecules and 
lipids. Baseline correction removes this signal after acquisition. The function which 
describes the course of the background signal can be subtracted, or the portion of 
the FID with broad signals can be removed (all signals influenced), or baseline 
signals are incorporated into the model function used for signal fitting.  
 
2.4. Analysis/ Signal Fitting & LCModel Software 
 
The signal acquired needs to undergo processing and the processed signal needs 
to be fitted to individual metabolites and the metabolite concentrations calculated.  
The software used in this work for processing, signal fitting and metabolite 
quantitation is LCModel (96), which is widely used and determines metabolite 
concentrations by fitting the data to a linear combination of basis functions formed 
from individual metabolite spectra (Fig.3). LCModel is automatic with no subjective 
input necessary, although default settings can be adjusted via the control file or 
additional post-processing modules incorporated. The uncertainties of the 
metabolite concentration estimates, the Cramér-Rao lower bounds, are also 
calculated by LCModel (95).  
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The software automatically accounts for the baseline (including residual water 
signal, susceptibility artifacts and macromolecule or lipid signals) and lineshape 
(eddy currents and field inhomogeneities). Parameters for zero order and first order 
phase corrections and overall referencing shift are included in the model.  For the 
data presented in this thesis, the LCModel analysis steps included zero-filling, 
Fourier transform, eddy current correction using the water reference, automatic 
zero and first-order phasing (with some constraints for GE data), frequency 
referencing and quantitation. It can be applied to all field strength and sequences, 
by selecting the appropriate model spectra (95). The concentrations obtained by 
LCModel analysis can be used individually, in ratios, or as part of pattern 
recognition methods, to provide information about the biological characteristics of 
the tumours, and answer specific clinical questions. Older studies tended to report 
ratios of metabolites, but more recently the concentrations of single metabolites are 
estimated by normalization to the area of the water peak (referencing to the water 
unsuppressed spectrum), with correction factors for assumed differences in T2 and 
the assumption of constant tissue water content (that of white matter).  
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                   Fig.3 LCModel fitted spectrum 
 
The main metabolites detected by short TE 1H MRS are: 
1) choline and choline-containing compounds (mainly phosphocholine (PCh) and 
glycerophosphocholine (GPC)) at 3.2ppm, which is a cell membrane and myelin 
marker 
2) total creatine  and phosphocreatine  at 3.0 ppm, which is a marker of brain 
energy metabolism 
3) N-acetyl aspartate (NAA) at 2.02ppm, which is a neuronal marker although there 
is much controversy about its function 
4) myoinositol (mIns) at 3.6ppm, an astrocyte marker and osmolyte 
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5) glutamate (Glu), a neurotransmitter, redox marker and when at pathologically 
increased concentration a neurotoxin, and glutamine (Gln), an astrocyte marker, 
summarized as a multiplet, Glx, at 2.2-2.4ppm 
6) glycine at 3.55ppm, an inhibitory neurotransmitter (75) 
7) lactate (Lac) at 1.3ppm, which is not seen in the healthy human brain but results 
from glycolysis 
8) and lipids/macromolecules (mainly at 0.9, 1.3 and 2.0 ppm).  
Some of these metabolites are illustrated in Fig.2. Long TE metabolites include 
total choline, creatine, NAA, lactate (seen as an inverted doublet at 135ms), 
glycine, and some lipids and macromolecules (decrease with increasing TE).        
(1, 49, 88) 
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CHAPTER 3 PATIENTS AND METHODS- SINGLE VOXEL MRS FOR 
DIAGNOSIS AND PROGNOSIS OF PAEDIATRIC LOW GRADE BRAIN 
TUMOURS 
 
3.1. MRS Acquisition 
   
MRS was performed routinely in children with brain tumours as part of the clinical 
imaging, at 1.5T (Siemens Symphony, GE Excite) or 3.0T (Philips Achieva), prior 
to any treatment (except stereotactic biopsy) at the Birmingham Children’s Hospital 
(BCH) and Queen’s Medical Centre (QMC), from 1st September 2003 to 31st March 
2009. This cohort of patients was followed-up and clinical, imaging, MRS and 
histopathological data collected, up to 31 May 2010 or the day of last clinical 
contact for the patient before this. All clinical data collected was stored in a 
Microsoft Access database designed for this purpose (Appendix 1), which enabled 
advanced queries to be created and facilitated the analysis of this complex set of 
data. The MRS acquisition protocol involved using point-resolved spectroscopy 
(PRESS) localization for a single voxel. The voxel volume was either 3.375cm3 or 
8cm3 according to the size of the tumour.  A TE of 30ms was used for most 
patients, with all spectra acquired at TEs of 23-41ms. Repetition time was 1500-
2000ms and 128 repetitions were used for 8cm3 voxels while 248 repetitions were 
used for 3.375 cm3 voxels. A water unsuppressed MR spectrum was acquired for 
eddy current correction and as a concentration reference. Τhe concentrations of 
single metabolites were estimated by normalization to the area of the water peak 
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(referencing to the water unsuppressed spectrum), with correction factors for 
assumed differences in T2 and the assumption of constant tissue water content 
(that of white matter). However, this does not give an accurate absolute 
concentration in millimolar units, as the water concentration can be significantly 
increased in pathological conditions such as brain tumours (92). Therefore the 
concentrations calculated are inaccurate by an unknown factor, and are obtained in 
“institutional units”, differing from mM by up to 20% (97).  
 
3.2. Spectral processing  
 
Raw MRS signal data and voxel position images were transferred to a dedicated 
computer network. The signal was processed using LCModel software (version 
6.2.0) (96) which determines metabolite concentrations by fitting the data to a 
linear combination of basis functions formed from individual metabolite spectra. 
1.5T and 3.0 T basis sets were used for the respective data. Cramer-Rao Lower 
Bounds (CRLB) were also determined by LCModel, and these indicate the 
accuracy with which the metabolite concentrations have been estimated.  
 
3.3. Quality Control 
 
The spectra were reviewed individually to assess quality, and the ones failing the 
criteria set were excluded from the analysis. These criteria included signal-to-noise 
ratio (S/N) ≥ 4 and full-width half-maximum (FWHM) ≤ 0.15ppm. Baseline stability, 
50 
 
good phasing, adequate water suppression and absence of artifacts were 
assessed by inspection. The voxel positioning was also reviewed to ensure the 
voxel was positioned over tumour and did not include large amounts of normal 
brain or cyst and was at least 3mm away from lipid-containing bone and scalp.   
The Crammer-Rao Lower Bounds (CRLB) were also reviewed and only 
metabolites where at least 2 patients had a CRLB < 30 were included (aspartate 
(Asp) and γ-Aminobutyric acid (GABA) were excluded from all analyses). The 
metabolite concentrations and CRLBs were automatically retrieved from the filing 
system using the Matlab code (1) in Appendix 2. Mean spectra were automatically 
produced using the Matlab code (2) in Appendix 2.  
 
As this is a multicentre study, Quality Control (QC) is also important in ensuring 
results from different scanners and centers can be combined. Work by Dr. Nigel 
Davies (98) has addressed this issue; protocols for QC have been implemented 
across six hospitals and nine MRI scanners. These protocols utilise phantoms of 
two different designs (Flood Phantom and Localisation Phantom) and volunteer 
scans to assess basic localisation efficiency, signal-to-noise ratio (SNR), water 
linewidth for shimming efficiency, water line-shape for eddy current distortions, 
effectiveness of eddy current (B0) correction and scalp lipid suppression. The 
Localisation Phantom is used to assess localisation efficiency and is scanned at 
least once on each scanner at the start of the study and after major scanner 
upgrades and has been performed on 7 scanners at 5 hospitals so far. The results 
from 4 scanners showed considerable variation in efficiency and contamination for 
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different scanner manufacturers, and this information can be used to calibrate the 
“true” voxel sizes indicated by the “nominal” voxel size for each scanner. The Flood 
Phantom consists of a polypropylene sphere containing metabolites to simulate a 
brain like spectrum. Each centre scans one of these phantoms at regular intervals 
using standard protocols (SVS and CSI). A preliminary analysis indicated 
variations of less than 10% in metabolite concentration measurements between 
scanners.  Normal adult volunteers have been scanned at 3 hospitals on 4 
scanners so far, with short and long TE SVS acquired with consistent voxel 
placement in the basal ganglia and parietal white matter.  Analysis of this data is 
pending. 
 
3.4. Statistics  
 
Statistical analysis was carried out in SPSS statistics software v. 17.0 and p-values 
of <0.05 were considered statistically significant.  Various statistical methods have 
been employed to analyze and assess spectroscopy results for diagnosis, 
prognosis and follow-up of paediatric low grade gliomas. These include simple 
comparisons of group means (independent samples t-test, paired samples t-test, 
ANOVA)(99), Receiver Operating Characteristic (ROC) curves, and logistic 
regression, as well as survival analyses (Kaplan-Meier curves, Cox regression).  
 
T-tests calculate Student’s t to compare sample means and display the probability 
of the difference between the means. Independent samples t-tests are used when 
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the same variable is compared for two groups of patients, and paired samples t-
tests when a different variable is compared for the same group of patients (e.g. first 
and second MRS) (99). One-way ANOVA gives a one-way analysis of variance for 
a quantitative dependent variable (e.g. metabolite) by an independent variable (e.g. 
type of tumour), and tests the hypothesis that several means are equal (99). 
 
ROC curves are used for binary classifications from a numerical variable, and can 
assess the performance of different cut-off values. A ROC curve is a plot of 
sensitivity against 1-specificity, for different cut-offs (100). ROC curves were used 
to define the best classification cut-offs to be used in binary logistic regression, and 
to dichotomise variables for survival analyses. Binary logistic regression uses 
predictor variables to predict a dichotomous outcome, such as the probability of a 
tumour being glial or glioneuronal. Multinomial logistic regression is similar, but the 
outcome variable can have more than two categories (99). 
 
Kaplan-Meier survival analysis estimates time-to-event models, when censored 
cases are present (censored cases are cases where the event has not occurred, 
e.g. patients who did not progress), using one independent variable. Variables 
found to have a significant effect on progression-free survival in Kaplan-Meier 
analysis were then used in a Cox regression to determine independent predictors 
or progression-free survival.   Cox regression also looks at time-to-event data; it 
builds a model which produces a survival function predicting the probability that the 
53 
 
event (e.g. progression) has taken place at a given time for given values of 
predictor variables (metabolites) (99). 
 
Ethical approval was given for all parts of the study presented in this thesis and 
written parental informed consent obtained. 
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CHAPTER 4 
1H MAGNETIC RESONANCE SPECTROSCOPY IN THE DIAGNOSIS OF 
PAEDIATRIC LOW GRADE BRAIN TUMOURS 
 
4.1. INTRODUCTION 
 
Low grade brain tumours include various histological entities of grade 1 and 2 
lesions, which although treated under the same protocol, have very different 
clinical courses and outcomes (9). The diagnoses range from cerebellar pilocytic 
astrocytomas (PA) which are usually resected surgically and do not progress (11, 
12), to complex optic pathway gliomas (OPG) with NF1 hamartomas, which are 
difficult to manage due to their site and multiple progressions (11, 13), and diffuse 
and pilomyxoid astrocytomas which are more aggressive (11). Glioneuronal 
tumours (gangliogliomas, dysembryoplastic neuroepithelial tumours (DNETs)), are 
also included in this group, as well as tectal plate gliomas (TPG) which are not 
biopsied and are usually observed without progression (11). Although clinical and 
MRI information give some indication as to the type of tumour, it is often difficult to 
discriminate between these very similar or even histologically identical tumours. 1H 
Magnetic Resonance Spectroscopy can detect tumour metabolites and 
lipids/macromolecules, and add unique information regarding the biology of the 
tumours, aiding clinical management in terms of the need to biopsy lesions and 
selection of appropriate treatment. It has shown promise in discriminating between 
different brain tumours in adults and children (27, 53-55, 63), although most 
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studies include various tumour types. This study includes an extensive bi-centre 
cohort of low grade brain tumours, and uses MRS to discriminate between them.  
 
Numbers of paediatric patients in previous studies is limited and those which have 
included children invariably include data from a single center.  In a study by 
Astrakas et al. which included 66 patients, with tumours of various histologies, 
choline and lipids and/or lactate have been shown to be higher in high grade 
tumours vs. low grade tumours (74). A study by Peet et al, which included 59 
patients, established differences between various tumour types (27) and a study by 
Panigraphy et al. found significant differences between the common childhood 
brain tumour types in pre-treatment MRS. Studies of specific tumour types are 
rarer but Harris et al. established differences in the MRS of pilocytic astrocytomas 
depending on location and produced pilot data showing that mIns could provide an 
important prognostic marker; Hwang et al. found elevated lactate and Cho/NAA of 
3.40 (66, 87). Multicentre studies are required to accrue sufficient cases to study 
specific tumour groups and also to demonstrate that consistent results can be 
obtained across various centers. Multi-centre studies have been published in 
adults from projects such as INTERPRET (101, 102) but such data is only just 
emerging in children (103). 
 
The aim of this study is to investigate a sufficiently large cohort of low grade brain 
tumours with MRS to allow differences between the subgroups of tumours to be 
established. Data is collected from several scanners from more than one centre 
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following common acquisition protocols, thereby establishing the credibility of the 
technique in a clinical environment.  
 
4.2. METHODS 
 
The methods for this study and the patients included are discussed in Chapter 2. 
The statistical analysis was carried out in SPSS statistics software v.17.0 and p-
values of <0.05 were considered statistically significant. The tests included two-
tailed independent samples T-Tests, ANOVA (Hochberg and Games-Howell), ROC 
curves and binary and multinomial logistic regression. The metabolites used as 
input for all T-Tests and ANOVA were: alanine (Ala), creatine (Cr), glucose (Glc), 
glutamine (Gln), glutamate (Glu), myo-inositol (mIns), lactate (Lac), scyllo-inositol 
(Scyllo), taurine (Tau), glycerophosphocholine (GPC), phosphocholine (PCh), 
guanidinoacetate (Gua), total choline (GPC+PCh), total NAA (NAA+NAAG), 
Glu+Gln, total lipids and macromolecules at 1.3 ppm (MM14+Lip13a+Lip13b), at 
0.9 ppm (MM09+Lip09) and 2.0 ppm (MM20+Lip20). The metabolites found to be 
significantly different in the T-tests and ANOVA were then used to build 
corresponding logistic regression classifiers. For each binary logistic regression 
classifier the best cutoff value (giving the highest sensitivity+specificity) for 
classifying a tumour in the reference category was determined using a ROC curve. 
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4.3. RESULTS 
  
108 patients had pre-treatment MRS (81 from BCH, 27 from QMC). 32 patients 
were excluded on quality control criteria (23 BCH, 9 QMC) and 7 patients were 
excluded due to missing data (1 BCH, 6 QMC). This left a cohort of 69 patients (57 
BCH, 12 QMC) who had pre-treatment MRS which passed quality control and were 
included in the analysis. The patient ages at the time of MRS ranged from 2-195 
months, mean 104 months, and there were 36 male and 33 female patients. 49 of 
the 69 patients had a biopsy (and 30 of the 39 patients excluded), all cases had 
their diagnosis reviewed by the local multidisciplinary team and central pathology 
review was undertaken in 43% of cases in the final cohort in the analysis (n=21). 
The diagnosis was altered after central pathology review in only 2 patients, and 
both were minor changes (1 from diffuse astrocytoma with extensive gemistocytic 
differentiation to diffuse astrocytoma fibrillary, and the other from low grade 
astrocytoma to pilocytic astrocytoma). The breakdown by diagnosis (summarized 
in Table 1) was: 19 posterior fossa biopsied Pilocytic Astrocytomas (PF PA), 9 
supratentorial PA and  unbiopsied optic pathway gliomas (STPA+OPG) without 
NF1, 7 STPA+OPG with NF1, 7 gangliogliomas, 6 diffuse astrocytomas (including 
fibrillary), 6 tectal plate gliomas (TPG) which includes a rosette forming 
glioneuronal tumour of the 4th ventricle (RFGNT), 5 dysembryoplastic 
neuroepithelial tumours (DNET) (biopsied and unbiopsied), 4 pilomyxoid 
astrocytomas (including 1 pilocytic/pilomyxoid tumour grade 1-2), 4 
neurofibromatosis bright objects (NBO), and 2 metastatic Pilocytic Astrocytomas 
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(MetPA) at presentation. NBOs were diagnosed on clinical and radiological 
features (they were all under observation only and did not progress). The biopsied 
tumours were categorized according to the World Health Organization (WHO) 
classification system 2007 (104). The term optic pathway glioma (OPG) is used in 
this paper to refer exclusively to tumours of the optic pathway which have not been 
biopsied. Since OPGs in children, particularly those with NF1, are invariably 
pilocytic astrocytomas, in the analysis, OPG have been combined with biopsy-
proven pilocytic astrocytomas. This combined group is referred to as PA+OPG (i.e. 
biopsied pilocytic astrocytomas + unbiopsied optic pathway gliomas) but is also 
subdivided according to NF1 status and site in the analysis (105).  Excluding 
metastatic PA, PA+OPG make up 51% of the tumour cohort.                                                                        
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Table 1. Summary of tumour types and patient numbers 
 
Tumour type Number of patients 
Posterior fossa pilocytic astrocytoma 19 
Supratentorial pilocytic astrocytoma + unbiopsied 
optic pathway glioma without NF1 
9 
Supratentorial pilocytic astrocytoma + unbiopsied 
optic pathway glioma with NF1 
7 
Ganglioglioma  7 
Diffuse astrocytoma 6 
Tectal plate glioma (includes a rosette forming 
glioneuronal tumour of the 4th ventricle) 
6 
Dysembryoplastic neuroepithelial tumour 5 
Pilomyxoid astrocytoma  4 
Neurofibromatosis bright object 4 
Pilocytic astrocytoma metastatic at presentation 2 
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An example of voxel positioning in a tumour is shown in Fig. 1. Mean spectra of 
different brain tumours are shown in Fig.2. Groups of tumours, represented in the 
tree structure in Fig. 3, were compared using T-Tests and ANOVA for the 
metabolite means (significant metabolite differences also shown in the figure).  
Logistic regression was also performed between the groups to provide classifiers 
which allow cases to be allocated to their most likely tumour type according to their 
MRS using the tree structure. The results are summarized in Table 3. It should be 
noted, however, that the number of patients in some groups is small (<10) and this 
may have biased the logistic regression coefficients and significantly influenced the 
validity of the models (106), which need to be tested on larger datasets. 
 
Fig. 1 Voxel placement over a frontal Dysembryoplastic Neuroepithelial Tumour   
          (DNET)     
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Fig.2 Mean spectra of low grade glioma subgroups +/- 1 standard error. mIns= 
myo-inositol, tCho= total choline, Cr= creatine, NAA= N-acetyl-aspartate, Lac=  
lactate, Lipids+MMs= lipids and macromolecules, PA= pilocytic astrocytoma, 
OPG= optic pathway glioma, NBO= neurofibromatosis bright object, PMA= 
pilomyxoid astrocytoma, TPG= tectal plate glioma, DNET= dysembryoplastic 
neuroepithelial tumour 
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Fig.3 Classification scheme for low grade brain tumours. Statistically significant 
metabolite differences given by the side of the boxes and refer to the tumour group 
closer to them e.g. glioneuronal tumours have significantly higher Cr and lower 
MM09+Lip09 and MM14+Lip13a+Lip13b compared to glial tumours. Cr=creatine, 
MM09+Lip09=lipids and macromolecules at 0.9ppm, MM14+Lip13a+Lip13b=lipids 
and macromolecules at 1.3ppm, Gln=glutamine, Lac=lactate, NAA+NAAG= total N-
acetyl aspartate, Scyllo=scyllo-inositol, mIns=myo-inositol, Ala=alanine 
↑ Cr 
↓MM09+Lip09 
↓MM14+Lip13a+Lip13b 
Tectal Plate Gliomas and Neurofibromatosis Bright Objects 
not included 
↑Gln 
↑Lac 
↓NAA+NAAG 
↑Lac 
↓mIns 
No significant difference 
↑Ala 
↓Cr 
↓Scyllo 
↓ mIns 
 ↓Scyllo 
↑Cr 
Low Grade 
Brain Tumour 
Glial 
n=47 
Glioneuronal 
n=13 
Pilocytic 
Astrocytoma, n=37  
n=37 
Other 
n =9 
DNET 
n=5  
Ganglioglioma 
n=7 
Supratentorial 
with NF1, n=7 
Supratentorial 
without NF1, 
n=9 
Posterior Fossa 
n=19 
Diffuse 
Astrocytoma, 
n=6 
Pilomyxoid 
Astrocytoma, 
n=4 
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Mean concentration values for all groups included in the comparisons and for all 
metabolites are shown in Table 2. Concentration values and means are in 
“institutional units” (referenced to water unsuppressed spectrum- described in 
Chapter 3). The logistic regression equations giving the probability of a tumour 
belonging to a certain group, the probability cutoff values, the area under the ROC 
curve and the ROC curve significances are given in Table 3.  
 
All glial tumours (N=47) were compared to all glioneuronal tumours (N=13), using 
an independent samples T-Test (4 NBOs and 5 TPGs excluded, RFGNT included). 
Cr (p<0.001) was found to be significantly higher and MM09+Lip09 (p=0.005) and 
MM14+Lip13a+Lip13b (p=0.032) significantly lower in glioneuronal tumours. Binary 
logistic regression to classify these tumours (using Cr, MM09+Lip09 and 
MM14+Lip13a+Lip13b) resulted in a sensitivity of 1 and a specificity of 0.745 
(reference category=glioneuronal).  
 
Within the glioneuronal group, gangliogliomas (N=7) were compared to DNETs 
(N=5) using an independent samples T-Test. Gln (p=0.017) and Lac (p=0.032) 
were significantly higher and NAA+NAAG (p=0.045) lower in gangliogliomas. PCh 
(p=0.051) approached significance and was higher in gangliogliomas. The binary 
logistic regression classifier included only NAA+NAAG. The sensitivity was 0.8 and 
the specificity 0.857 (DNET is considered to be the positive result).  
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4.3.1. Comparison of Pilocytic Astrocytomas with Other Glial Tumours 
 
 PA+OPG+MetPA (N=37) were compared to other glial tumours (PMA, Diffuse) 
(N=9) using a t-test and Lac was found to be significantly higher and mIns 
significantly lower in PA+OPG+MetPA (p=0.017 and 0.008 respectively). The 
logistic regression model (variables: Lac and mIns) gave a sensitivity of 0.889 and 
a specificity of 0.676 (positive result=other glial).  
 
PA+OPGs (N=35) were compared to diffuse astrocytomas (N=6) (grade 2) using 
an independent samples T-Test. Cr (p=0.007), NAA (p=0.040) and mIns (p=0.005) 
were found to be significantly higher in diffuse astrocytomas and Lac (p=0.040) 
significantly lower. The logistic regression model (variables: Cr, NAA, mIns and 
Lac) gave a sensitivity of 1 and a specificity of 0.771 (positive result=diffuse 
astrocytoma).  
 
Supratentorial PA+OPG without NF1 (n=9) were compared to PMA (n=4) using an 
independent samples T-Test and no significant differences were found. Posterior 
fossa PAs (n=19) were compared to MetPAs (n=2) using an independent samples 
T-Test, and MetPAs were found to have significantly higher GPC+PCh (p=0.044) 
and Glu+Gln (0.050). All PA+OPG were compared with MetPA+PMA and no 
significant differences were found. Diffuse astrocytomas were compared to PMA (t-
test) and no significant differences were found.  
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4.3.2. Pilocytic Astrocytomas and Optic Pathway Gliomas 
 
The differences within the PA+OPG group were further investigated, as this is the 
biggest cohort and previous work has shown that MRS can detect differences by 
site of tumour (66). In addition, the differences by neurofibromatosis type 1 (NF1) 
status were investigated, as optic pathway tumours are prevalent in patients with 
NF1(8). An independent sample t-test comparing all supratentorial PA+OPG 
(n=16) with posterior fossa PA (n=19) showed Cr (p=0.002), Scyllo (p<0.001), Tau 
(p=0.042) and mIns (p=0.001) to be significantly higher in the supratentorial 
tumours.  
 
Using ANOVA to compare the three groups,  STPA+OPG in patients with NF1, 
without NF1 and posterior fossa PAs showed posterior fossa PAs to have 
significantly higher Ala (p=0.050) and lower Cr (p=0.001), Scyllo (p=0.008) and 
mIns (p=0.011) than STPA+OPG with NF1; posterior fossa PAs to have 
significantly lower Scyllo (p= 0.028) than STPA+OPG without NF1;  STPA+OPG 
with NF1 to have significantly higher Cr (p=0.043) than those without NF1. A T-
Test comparing STPA+OPG with and without NF1 also shows Cr (p=0.022) to be 
significantly higher in STPA+OPG with NF1, in addition to mIns (p=0.041), and Ala 
to be lower in STPA+OPG with NF1 (p=0.014). Multinomial logistic regression to 
classify the 3 groups of pilocytic astrocytomas (variables: Ala, Cr, mIns, Scyllo) 
yielded a classification accuracy of 95% for posterior fossa PA (N=19), 86% for 
STPA+OPG with NF1 (N=7) and 78% for STPA+OPG without NF1 (N=9). The 
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equations giving the probability of a tumour being a member of one of these groups 
are given in Table 3.  
 
Comparing STPA+OPG in patients with NF1 with NBOs, yielded many significant 
differences; NBOs have significantly higher Cr (p=0.017), Glu (p<0.001), Glu+Gln 
(p=0.044) and NAA+NAAG (p<0.001) and significantly lower MM09+Lip09 
(p=0.047) and MM20+Lip20 (p=0.049).  
 
Posterior fossa PAs were compared to TPGs using an independent samples T-
Test. Many significant differences were found, including significantly higher Cr 
(p=0.004), GPC (p=0.029), GPC+PCh (p=0.002), Glu+Gln (p=0.047), NAA+NAAG 
(p=0.001), Scyllo (p=0.014) and mIns (p=0.006) in TPG and significantly lower Lac 
(p=0.012), MM09+Lip09 (p=0.042) and MM13+Lip13a+Lip13b (p=0.002) in TPG. 
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Table 2. Mean concentration values for all metabolites analysed for all low grade glioma subgroups/comparisons in text.  Mean= mean 
concentration value, GN=glioneuronal, PA+OPG=biopsied pilocytic astrocytomas and unbiopsied optic pathway gliomas, ST 
PA=supratentorial pilocytic astrocytoma, Post. Fossa PA=posterior fossa pilocytic astrocytoma, MetPA=metastatic pilocytic astrocytoma, 
PMA=pilomyxoid astrocytoma, DA=diffuse astrocytoma, DNET=dysembryoplastic neuroepithelial tumour, GG=ganglioglioma, 
NBO=neurofibromatosis bright object, TPG=tectal plate glioma 
 Glial 
(N=47) 
GN 
(N=13) 
All 
PA+   
OPG 
(N=35)  
ST 
PA+ 
OPG 
with 
NF1 
(N=7) 
ST 
PA+ 
OPG 
no 
NF1 
(N=9) 
All ST  
PA 
(n=16) 
Post. 
Fossa 
PA 
(N=19) 
PA+ 
OPG+
MetPA 
(N=37) 
MetPA 
(N=2) 
PMA 
(N=4) 
Other 
Glial 
(DA+ 
PMA) 
(N=9) 
DA 
(N=6) 
PMA+ 
MetPA 
(N=6) 
DNET 
(N=5) 
GG 
(N=7) 
NBO 
(N=4) 
TPG 
(N=6) 
 Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean 
Ala 0.80 0.78 0.84 0.23 0.98 0.65 1.00 0.82 0.51 1.23 0.55 0.36 0.99 0.46 1.03 0.08 0.47 
Cr 1.15 2.35 1.00 2.32 1.02 1.58 0.51 1.02 1.32 0.61 1.74 2.29 0.85 2.26 2.47 3.55 3.24 
GPC 0.78 0.73 0.75 0.97 0.70 0.82 0.69 0.74 0.64 0.45 0.90 1.24 0.51 0.89 0.58 1.20 1.17 
GPC+ PCh 1.22 1.09 1.20 1.64 1.25 1.42 1.03 1.22 1.54 0.92 1.23 1.42 1.13 0.89 1.24 1.61 1.54 
Glc 0.85 0.80 0.88 0.84 0.71 0.77 0.98 0.86 0.40 0.99 0.70 0.69 0.79 0.99 0.57 1.10 1.10 
Gln 2.52 2.79 2.55 2.57 3.34 3.00 2.17 2.58 3.07 2.37 2.26 2.25 2.61 1.62 3.86 2.31 2.42 
Glu 1.54 2.48 1.40 1.42 1.40 1.41 1.40 1.46 2.39 2.18 1.77 1.63 2.25 2.27 2.77 3.25 2.36 
Glu+Gln 4.06 5.28 3.95 3.99 4.74 4.41 3.56 4.03 5.46 4.56 4.03 3.88 4.86 3.89 6.63 5.56 4.78 
Gua 1.08 1.42 1.03 0.64 1.10 0.90 1.14 1.12 2.63 1.02 0.93 0.91 1.56 1.10 1.63 0.80 1.14 
Lac 2.36 1.48 2.67 1.46 3.14 2.40 2.90 2.64 2.08 2.03 0.94 0.85 2.05 0.67 2.20 0.54 0.75 
MM09+       
Lip09 
6.40 3.94 6.66 5.02 7.04 6.16 7.09 6.67 6.72 6.21 4.63 4.89 6.38 2.82 4.71 2.91 3.48 
MM14+       
Lip13a+     
Lip13b 
10.76 5.22 10.68 7.99 12.42 10.48 10.85 10.56 8.43 13.60 10.68 10.15 11.88 2.29 7.37 3.40 4.31 
MM20+       
Lip20 
7.81 7.28 7.73 8.81 8.44 8.60 6.99 7.71 7.49 6.99 7.81 8.93 7.16 5.50 8.37 6.30 6.58 
NAA+ NAAG 1.13 1.88 1.01 1.09 1.27 1.19 0.86 1.04 1.41 1.37 1.28 1.52 1.38 2.81 1.20 2.96 2.07 
PCh 0.44 0.35 0.46 0.67 0.55 0.60 0.34 0.48 0.90 0.48 0.33 0.18 0.62 0.00 0.66 0.40 0.36 
Scyllo 0.07 0.12 0.05 0.13 0.07 0.10 0.01 0.06 0.23 0.07 0.15 0.17 0.12 0.14 0.09 0.17 0.26 
Tau 0.14 0.18 0.15 0.41 0.21 0.30 0.02 0.14 0.02 0.21 0.18 0.13 0.15 0.15 0.23 0.42 0.61 
mI 2.22 3.31 1.81 4.24 2.13 3.06 0.76 1.86 2.72 2.37 3.88 4.36 2.49 3.82 2.86 5.58 7.42 
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Table 3. Logistic Regression analysis equations, probability cutoff values, areas under the ROC curve and ROC curve significances. 
DNET=dysembryoplastic neuroepithelial tumour, PA=pilocytic astrocytoma, OPG=unbiopsied optic pathway glioma, MetPA= metastatic 
pilocytic astrocytoma, NF1=Neurofibromatosis type 1, Cr=creatine, Lip09+MM09=lipids and macromolecules at 0.9ppm, 
MM14+Lip13a+Lip13b= lipids and macromolecules at 1.3ppm, NAA=N-Acetylaspartate, NAAG=N-Acetylaspartylglutamate, Lac=lactate, 
mIns=myo-inositol, Ala=alanine, Scyllo=scyllo-inositol
 Binary Logistic Regression Equations  Probabi-
lity cutoff 
value 
Area 
under 
ROC 
curve 
ROC 
curve 
signifi-
cance 
Glial vs 
Glioneuronal 
Prob(glioneuronal)= 1/(1+e^-z) 
z= -1.3 + (0.871*Cr) + (-0.240*Lip09MM09) + (-0.044*MM14Lip13aLip13b) 
0.18 0.867 
 
p<0.0001 
DNET vs 
Ganglioglioma 
Prob(DNET)=1/(1+e^-z) 
z=  -2.368 + (1.072*NAANAAG) 
0.34 0.857 p=0.042 
PA+OPG+Met PA 
vs Other Glial 
Tumours 
Prob(other glial)= 1/(1+e^-z) 
z= -0.479 + (-1.054*Lac) + (0.263*mIns) 
0.12 0.868  
 
p=0.001 
PA+OPG vs 
Diffuse 
Astrocytoma 
Prob(Diffuse)= 1/(1+e^-z) 
z= -3.113 + (-1.047*Lac) + (0.235*mIns) + (0.149*Cr) + (1.867*NAA) 
0.09 
  
 
0.919 p=0.001 
 Multinomial Logistic Regression Equations 
Supratentorial 
PA+OPG with 
NF1 vs 
Supratentorial 
PA+OPG without 
NF1 
Prob(ST_with_NF1)=1/(1+e^-z) 
z=   -1.819 + (-5.559*Ala) + (1.212*Cr) + (0.912*mIns) + (-4.821*Scyllo) 
Posterior Fossa 
PA vs 
Supratentorial 
PA+OPG without 
NF1 
Prob(PF PA)= 1/(1+e^-z) 
z= 5.651 + (-0.057*Ala) + (-0.359*Cr) +(-3.039*mIns) + (-33.871*Scyllo) 
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4.4. DISCUSSION 
 
 This study shows that MRS has the ability to discriminate between the different 
tumour groups of paediatric low grade brain tumours, many of which are very 
similar radiologically and histologically. The main differences can be readily 
identified on visual inspection of the spectra and mean spectra have been 
presented to aid this. Quantitative analysis of the spectra to yield metabolite 
concentrations can further aid the identification of specific subgroups by 
comparison with mean values and logistic regression equations can be used to 
give a more formal classification in cases where the tumour type is difficult to 
discern by visual inspection of the spectra. The collection of data from more than 
one centre has allowed rarer tumour types to be investigated and also established 
that MRS can be applied across centers with success in this challenging tumour 
group. 
 
Previous work on a small cohort, showed differences between STPA+OPG  and 
cerebellar PA , with supratentorial tumours having significantly higher Ins and 
Glu+Gln (66). In our study, a comparison of all supratentorial PA+OPG with 
posterior fossa PAs confirmed that mIns is significantly higher in supratentorial 
tumours, but also found Cr, Scyllo, and Tau to be significantly higher. A 
comparison of supratentorial PA+OPG with and without NF1 and posterior fossa 
PAs revealed significant differences between these three groups and multinomial  
logistic regression showed that the group of PA+OPG can be subdivided according 
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to site and NF1 status. A review of the MR images did not reveal any obvious 
correlation with conventional MR characteristics according to NF1 status. This is a 
promising finding as MRS can detect differences in a group of tumours which is 
histologically identical and more importantly could hold prognostic information as 
patients with NF1 usually have more indolent disease. A proportion of brain 
gliomas in patients with NF1 remain stable and may spontaneously regress (68) 
and the MRS profile of these tumours may be representative of tumours which 
have a better clinical course.  
 
An abnormality found in 43-93% of children with NF1 are neurofibromatosis bright 
objects (NBOs), which are seen as areas of increased T2 signal on MRI (107). It 
can be  difficult to detect differences radiologically between NBO, which are benign 
and often resolve spontaneously in the second decade, and brain gliomas (68). 
There can be multiple NBOs throughout the brain, and a non-invasive method of 
discriminating these from PAs would aid clinical decision making. MRS is showing 
promise at being able to solve this question. In a study of brain lesions in children 
with NF1 by Wilkinson et al. (68), Cho and mIns were significantly higher in 
tumour/atypical NBO compared to typical NBO and control groups. Gonen et 
al.(69) found that focal areas of signal intensity (FASI) in children with NF1 had 
significantly elevated Cho, reduced creatine, 2>Cho/Cr>1.3 and nearly normal 
NAA, and differed from tumours which had no NAA and Cho/Cr>2. Barbier et al. 
(108) found lower NAA/Cr, NAA/mIns, NAA/Cho and higher mIns/Cho in the right 
lateral thalamus of children with NF1 who had unidentified bright objects (UBO) 
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compared to those without UBO. Interestingly, the site of the metabolic differences 
was not the site of the T2 hyperintensities. Our comparison of ST PA+OPG with 
NF1 and NBOs showed that NBOs have significantly higher Cr, Glu, Glu+Gln, total 
NAA, and significantly lower MM09+Lip09 and  MM20+Lip20. Although the number 
of NBOs is small, this is a promising result as there seem to be multiple 
differences, some of which may be expected from previous work. For example 
NAA may have been expected to be higher in NBOs as they are more diffuse and 
perhaps have more normal brain entrapped, which would increase NAA, a 
neuronal marker (74). NAA is mainly a component of healthy neurons, and the 
origins and functions of NAA which is seen in tumours are still under debate. For 
diffuse tumours, it may simply indicate the presence of neurons in brain which has 
been infiltrated by tumour. However, NAA may also be present in immature 
oligodendroglia and could be seen in neoplastic changes (74, 109). NAA was also 
higher in TPG and diffuse astrocytomas compared to PAs and these are more 
diffuse tumours with more entrapped normal brain. In addition, lipids and/or lactate 
have been shown to be increased in higher grade tumours (74), and in our results 
lipids were higher in PA than NBOs as expected.  
 
Due to their location and the surgical challenge they present, as well as the 
indolent course they usually follow, tectal plate gliomas are often not biopsied to 
obtain a definitive histological diagnosis (11). Following imaging, they are 
commonly observed without treatment (11), making a firm non-invasive diagnosis a 
key component of their management. Different types of pathology have been 
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described in this region of the brain in adults and children, including pilocytic 
astrocytoma and high grade astrocytoma (110, 111). Improved non-invasive 
characterization of tumours in this region is therefore important. Comparing these 
TPG with posterior fossa PAs shows that MRS can detect many significant 
differences and shows that TPGs are biologically distinct from pilocytic 
astrocytomas.  
 
Although the numbers in some groups are small, the results of this study are in 
agreement with those predicted based on the literature and known clinical and 
biological behavior of the tumours. For example, choline has been linked to cell 
proliferation (58, 112), malignancy and higher grade tumours (74), and our results 
show a higher total choline in metastatic PAs than focal PAs.  Furthermore, mIns is 
high and lipids low in TPG, which generally have a more indolent course compared 
to PAs, and both of these metabolites have been similarly associated with lower 
grade tumours (57, 74).     
 
4.5. CONCLUSION  
 
This study shows that MRS can detect differences between subgroups of low 
grade brain tumours in children. The main differences can be readily identified on 
visual inspection of the spectra and quantitative analysis can aid the process of 
interpretation, making MRS a valuable aid to non-invasive diagnosis. The detection 
of metabolite differences between tumours of the same histology emphasizes the 
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potential for metabolite profiles to improve the characterization of these tumours 
and its combination with emerging molecular genetic biomarkers should improve 
the assessment of these tumours. Some of the most discriminatory metabolites are 
known to be important prognostic markers in other tumour groups, and future work 
is needed to determine whether they can predict progression-free survival in low 
grade gliomas in children.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
CHAPTER 5 
 
MAGNETIC RESONANCE 
SPECTROSCOPY IN THE 
PROGNOSIS AND FOLLOW-
UP OF LOW GRADE BRAIN 
TUMOURS 
 
 77 
 
 
CHAPTER 5 
 
 MAGNETIC RESONANCE SPECTROSCOPY IN PROGNOSIS AND 
TREATMENT- MONITORING OF LOW GRADE BRAIN TUMOURS 
 
5.1. INTRODUCTION 
 
 Low grade gliomas and their treatment may cause significant morbidity, in terms of 
physical deficits, neuropsychological and neuroendocrine effects (8).  Although 
overall survival (OS) rates are very high, progression-free survival (PFS) is much 
lower. In a study by Fisher et al.  5 and 10 year (from initial surgery) OS for low 
grade astrocytomas was 87% and 83%, and PFS was 55% and 42% (10, 15). A 
significant number of children have recurrences after surgical resection or progress 
after incomplete tumour resection or biopsy (9), which means that a non-invasive 
method for predicting prognosis and thus modifying initial treatment  is extremely 
important. In addition, the clinical symptoms and signs and the magnetic 
resonance imaging (MRI) characteristics of these tumours are not always 
straightforward to interpret. A tumour may appear to be getting smaller on MRI but 
the patient’s vision may be deteriorating and vice versa.  
 
Low grade tumours present multiple management challenges, as they can have 
similar clinical presentations, magnetic resonance imaging (MRI) characteristics, 
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and even histopathological features when biopsied, whilst simultaneously having 
very different responses to treatment.  
 
The aim of this study is to use 1H MRS to predict progression-free survival in an 
extensive cohort of low grade brain tumours specifically, by short echo time MRS 
pre-treatment, and to combine results from 2 centers. This is very important as 
getting multicentre data which follow the same acquisition protocols, are collected 
consistently, and have accurate clinical data over a long period of time and in 
patients with complicated clinical courses is very challenging, but the only way to 
increase the number of patients in these studies and get more reliable and 
statistically meaningful results. Another part of this study investigates metabolite 
changes in sequential MRS studies and correlates this with clinical data.  
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5.2. PATIENTS AND METHODS 
 
The patients and methods are described in Chapter 3. Progression is difficult to 
define in low grade brain tumours, as there are often discrepancies between 
imaging, clinical and histopathological data. Progression was therefore defined by 
the decision by the neuro-oncology multi-disciplinary team to change treatment, 
therefore taking into account all available information and being directly relevant to 
clinical practice.  
 
5.3. RESULTS 
 5.3.1. Prognosis 
 
The tumour cohort in this study is the same as in the study on diagnosis of low 
grade brain tumours with 1H MRS (except for one patient who was removed as 
progression occurred before the pre-treatment MRS). The cohort therefore 
consisted of 68 patients. The ages at pre-treatment MRS ranged from 2-195 
months, with a mean age of 103 months.  
 
Tumour diagnoses in accordance to the WHO classification, split by progression 
status are shown in Table 1.Treatments received in the first episode (i.e. from 
presentation to progression or end of follow-up), split by progression status are 
shown in Table 2.  
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Further analysis excluded patients with a complete or near complete resection and 
diffuse astrocytomas, leaving a cohort of 49 patients. 15 patients progressed (2 
died) in the duration of the study. Mean spectra of progressors and non-
progressors are shown in Fig.1.  
 
Table 1 Diagnoses (according to WHO), split by progression status. 
ST=supratentorial, PA = pilocytic astrocytoma, OPG=unbiopsied optic pathway 
glioma, NF1=neurofibromatosis type 1, NBO=neurofibromatosis bright object, 
DNET=dysembryoplastic neuroepithelial tumour, RFGT= rosette forming 
glioneuronal tumour of the 4th ventricle 
 
 Progressed Not 
progressed 
Total number 
of patients 
ST PA+OPG with NF1 3 4 7 
ST PA+OPG without 
NF1 
2 6 8 
Posterior fossa PA 1 18 19 
Pilomyxoid 
astrocytomas (1 
pilocytic/pilomyxoid) 
2 2 4 
NBO 0 4 4 
PA metastatic at 
presentation 
1 1 2 
Diffuse astrocytomas 
(including fibrillary) 
4 2 6 
Tectal plate gliomas 
(includes a rosette 
forming glioneuronal 
tumour of the 4th 
ventricle) 
 
1 (RFGT) 5 6 
Gangliogliomas 3 4 7 
DNET (biopsied and 
unbiopsied) 
2 (biopsied) 3 5 
 Total=19 Total=49 Total=68 
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Table 2 First episode treatments, split by progression status. Surgical resection is 
judged on MR imaging.  Surgery R1+R2= complete or near complete resection, 
Surgery R3+R4=incomplete resection or open biopsy or stereotactic biopsy   
 
 Progressed Not 
progressed 
Total 
number of 
patients 
Observation only 5 17 22 
Surgery R1+R2 0 13 13 
Surgery R3+R4 6 13 19 
Chemotherapy 1 1 2 
Surgery 
R3+R4+Chemotherapy 
5 4 9 
Surgery 
R3+R4+Radiotherapy 
2 1 3 
 Total=19 Total=49 Total=68 
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Fig.1 A. Mean spectrum of patients who did not progress +/- standard error  
          B.Mean spectrum of patients who progressed +/- standard error  
                   
ppm 
Intensity 
Intensity 
ppm 
A 
B 
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mIns was dichotomised using a ROC curve where the positive result was ‘not 
progressed’, and using the value giving the highest sensitivity + specificity, which 
was 4.1095. 31 patients had low mIns, and 14 of these progressed, whereas 18 
patients had high mIns and only 1 progressed. Patients with high mIns had 
significantly better progression-free survival (PFS) than those with low mIns (log-
rank significance=0.005). The survival curve (time in months) is shown in Fig. 2.  
 
Fig.2. Kaplan-Meier survival curve based on mIns concentrations.  
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GPC was dichotomised using a ROC curve where the positive result was ‘not 
progressed’, and using the value giving the highest sensitivity+specificity, which 
was 1.171. 32 patients had low GPC, and 13 of those progressed, whereas 17 
patients had high GPC and 2 of those progressed. Results approached 
significance, with patients having high GPC showing better progression-free 
survival (PFS) than those with low GPC (log-rank significance=0.057).  The 
survival curve (time in months) is shown in Fig. 3.  
 
Fig.3. Kaplan-Meier survival curve based on GPC concentrations.  
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PCh was dichotomised using a ROC curve where the positive result was 
‘progressed’, and using the value giving the highest sensitivity + specificity, which 
was 1.696. 46 patients had low PCh, and 13 of those progressed, whereas 3 
patients had high PCh and 2 of those progressed. Patients with high PCh had 
worse progression-free survival (PFS) than those with low PCh (log-rank 
significance= 0.047), although it should be noted that there are only 3 patients in 
the ‘high’ category.  
 
Cox regression included 15 patients who progressed and 34 who did not. A 
stepwise forward likelihood ratio (LR) method was used. Variables included in Cox 
regression are the ones found to have a significant or near significant effect on 
survival in Kaplan-Meier analysis. Reference categories are always the ‘high’ 
group.  mIns and PCh are included in the final model as significant predictors of 
survival.  Patients with low PCh (<1.696) have 0.153 times the risk of progression 
compared to those with high PCh (p=0.026). Patients with low mIns (<4.1095) have 
11.980 time the risk of progressing compared to those with high mIns (p=0.018). 
The -2 log likelihood of the model has a significance of 0.005 at step 1 and 0.002 at 
step 2, which means the model is significantly better than the null model.  Survival 
functions are shown in Fig. 4.  
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Fig. 4. Survival functions produced by Cox regression analysis. A- survival function 
at mean of covariates, B- survival function for mIns, C-survival function for PCh. 
mIns=myo-inositol, PCh=Phosphocholine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
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5.3.2. Follow-up  
 
A summary of the follow-up results is given in Table 3. Patients who did not 
progress and were only observed were investigated (n=10), and their first two 
good-quality MRS studies compared.  The diagnoses of these patients included 3 
NBOs, 3 TPGs, 2 DNETs, 1 ganglioglioma and 1 ST PA with NF1. Paired samples 
t-test showed a statistically significant difference between the first and second 
MRS in Lip13b (p=0.043), MM20 (p=0.025), MM20+Lip20 (0.030) and PCh 
(p=0.045). All metabolites had lower concentrations in the second MRS.  
 
Patients who did not progress and had MRS pre-treatment and after incomplete 
resection (surgery R3+R4) or observation followed by incomplete resection 
(surgery R3+R4) were investigated (n=3). The diagnoses of these patients 
included 1 diffuse astrocytoma, 1 ST PA without NF1 and 1 posterior fossa PA. 
Paired-samples t-test did not show any significant differences between the two 
MRS studies.  
 
Patients who did not progress and had MRS pre-treatment and during or after 
chemotherapy or radiotherapy or surgery R3+R4 or a combination of treatments 
were investigated (n=6). The diagnoses included 1 ST PA with NF1, 1 ST PA 
without NF1, 1 PA metastatic at presentation, 2 PMA and 1 diffuse astrocytoma. 
One patient had radiotherapy and the second MRS used in the analysis was 
performed approximately 3 months after radiotherapy. Paired samples t-test 
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showed a statistically significant difference between the first and second MRS in 
Ala (p=0.021) and MM12 (p=0.016); both metabolites had lower concentrations in 
the second MRS.  
 
Patients who progressed (looking at first progression) and had MRS pre-treatment 
and before progression were investigated (n=11), choosing the MRS which was 
closest to but before progression. Patients had varying treatments including 
observation, surgery, chemotherapy, radiotherapy or a combination. Diagnoses 
included 2 ST PA without NF1, 1 ST PA with NF1, 1 PF PA, 1 PA metastatic at 
presentation, 1 PMA, 1 DNET, 1 ganglioglioma, 1 RFGT, and 2 diffuse 
astrocytomas. 2 patients had radiotherapy and their second MRS in the analysis 
was right after and approximately 8 months after radiotherapy respectively. Paired 
samples t-test showed a statistically significant difference between the first and 
second MRS in Gln (p=0.041), with this metabolite having a higher concentration in 
the second MRS study.  
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Table 3. Summary of results from MRS follow-up. The first and second good 
quality MRS studies were compared, the first being pre-treatment and the second 
during or after the treatment in column 1. For the patients who progressed, the 
second MRS was before progression.  
Chemo= chemotherapy, Radio=radiotherapy, Obs=observation, Surg=surgery, 
NBO=neurofibromatosis bright object, TPG=tectal plate glioma, 
DNET=dysembryoplastic neuroepithelial tumour, Ganglio=ganglioglioma, 
STPA=supratentorial pilocytic astrocytoma, DA=diffuse astrocytoma, PF 
PA=posterior fossa pilocytic astrocytoma, PA met at pres=pilocytic astrocytoma 
metastatic at presentation, PMA=pilomyxoid astrocytoma, RFGT=rosette forming 
glioneuronal tumour of the 4th ventricle 
 
Treatment 
category 
Progression  Diagnoses Statistically significant 
differences between 1st and 2nd 
MRS 
Observation 
only 
No NBO n=3 
TPG n=3 
DNET n=2 
Ganglio n=1 
STPA with NF1 n=1 
Lip13b 
 
p=0.043 Lower 
in 2nd 
MRS MM20 p=0.025 
MM20+Lip20 
 
p=0.030 
PCh p=0.045 
Incomplete 
resection  
No DA n=1 
STPA no NF1 n=1 
PF PA n=1 
none 
Chemo/ 
Radio/ 
incomplete 
resection/ 
combination 
No STPA with NF1 n=1 
STPA no NF1 n=1 
PA met at pres n=1 
PMA n=2 
DA n=1 
Ala p=0.021 Lower in 
2nd 
MRS 
MM12 p=0.016 
Obs/ Chemo/ 
Radio/ Surg/ 
Combination 
Yes STPA no NF1 n=2 
STPA with NF1 n=1 
PF PA n=1 
PA met at pres n=1 
PMA n=1 
DNET n=1 
Ganglio n=1 
RFGT n=1 
DA n=2 
Gln p=0.041 Higher in 
2nd MRS 
study 
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5.4. DISCUSSION 
 
This study has investigated a large cohort of patients with low grade brain tumours 
over a long time period with respect to progression-free survival (PFS) and 
sequential spectral profile changes. Short echo time MRS pre-treatment was used 
to predict prognosis, and follow-up MRS studies were used to monitor changes in 
tumours. Although this is the largest cohort of low grade brain tumours for which 
this kind of data is reported in the literature, the number of patients and 
progression events is still low and therefore limits the power of the results. 
However, significant results have been demonstrated, data from 2 centers 
combined, and a detailed method of following-up patients with low-grade brain 
tumours and collecting MRS data alongside clinical, imaging and histopathological 
information established.  
 
In the investigation of PFS, tumours which were completely resected and diffuse 
astrocytomas were removed from the analysis, and the rest were grouped 
together. Gross total resection is the most consistent good prognostic factor (11, 
12). Non-pilocytic gliomas, particularly diffuse fibrillary gliomas, are more highly 
associated with progression, and tumour histology may be independent predictor of 
progression (11, 12).   Whilst other prognostic factors such as age and metastatic 
disease are emerging as important prognostic factors, the relatively small numbers 
of patients in the study prevented any further subcategorisation. 
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Pre-treatment MRS was shown to be predictive of progression-free survival using 
Kaplan-Meier survival analysis and Cox regression analysis, with high mIns, high 
GPC and low PCh being indicators of good prognosis. mIns was also shown by 
Harris et al. (66) to  be significantly lower at pre-treatment short TE SVS in children 
with supratentorial pilocytic astrocytomas who progressed compared to those with 
stable disease. Peet et al.(27) demonstrated myoinositol (Inos)/Cho to be 
significantly lower in untreated compared to treated brain tumours. NAA/Cho and 
Cr/Cho have been shown by Girard et al. (77) to be lower in patients who died, and 
the percent change in Cho/NAA and normalised choline was significantly higher in 
patients with progressive compared to stable outcomes in a study by Tzika et 
al.(79). Warren et al. found that patients with Cho/NAA equal to or below the 
median had greater survival (80). Other studies have also shown high choline or 
Cho/NAA to be linked to poor prognosis (progression or death) (62, 78, 81). 
However, none of these studies reported PCh and GPC separately. This is 
because it is difficult to separate these two metabolites in vivo at 1.5T, although a 
study by Wilson et al. (113) found a significant correlation between PCh from in 
vivo MRS and ex vivo HR-MAS, especially in medulloblastomas which have high 
PCh and excellent SNR (due to their high cellular density). This also allows the 
PCh peaks downfield from the PCh and GPC singlets at 3.2ppm to be detected. 
Furthermore, in a study of paediatric cerebellar tumours by Davies et al. (114), 
PCh was found to be an important discriminator of medulloblastomas. The 
LCModel basis set included GPC and PCh, and although the small chemical shift 
difference between their singlets is not considered enough to distinguish them in 
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vivo at 1.5T, it is suggested that the relative differences in concentrations of 
choline-containing metabolites lead to subtle but detectable changes in the total 
choline peak in the spectra. This was further supported by the narrower choline 
peak relative to the corresponding water peak width in medulloblastomas, which 
are known to have a predominant contribution from PCh.  
 
Lipids have also been implicated in progression and poor survival (62, 73, 81); in 
this study lipids at pre-treatment MRS were not identified as prognostic indicators, 
but follow-up MRS showed that patients with stable disease had a significant 
decrease (between pre-treatment and subsequent MRS) in lipids, macromolecules, 
PCh and Ala or no change in spectral profile, depending on the treatment group. 
This shows that patients with stable disease show a decrease in metabolites 
associated with more aggressive tumours, although this depends on the specific 
group of patients being investigated. Lazareff et al. (82) also found the ratio of 
tumour/brain choline to decrease significantly after treatment in patients with a 
decrease or stable tumour volume. However, they did not find normalised choline 
pre-treatment to be different between responders and non-responders to therapy, 
although post-treatment choline was significantly higher in then non-responders. 
Harris et al. showed that children with supratentorial pilocytic astrocytomas who 
progressed had a significant decrease in myoinositol between the pre-treatment 
and first on-treatment MRS (66), which we did not find in this study. Alanine, also 
shown to decrease between MRS studies in patients with stable disease, increases 
in hypoxic tissues due to increased glycolysis and has been observed in various 
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brain tumours(115), although its detection is difficult due to the low concentrations 
seen. Mirbahai et al.(116) showed alanine in nutrient starved and cisplatin treated 
BT4C cells to decrease, suggesting it may be a biomarker of cell stress and cell 
death.  
.  
Patients who progressed were found to have a significantly higher Gln on the 
second MRS (prior to prognosis) compared to the pre-treatment MRS, suggesting 
that Gln may be an earlier indicator of disease status than conventional imaging 
and clinical characteristics. Harris et al. (66) found that patients with supratentorial 
pilocytic astrocytomas who progressed had a tendency to lower 
glutamate+glutamine, although this did not reach significance; as glutamate and 
glutamine were combined in that study, it is difficult to compare the results.  
 
Although it is difficult to directly compare the results of the reported studies, as they 
use different methodologies (single voxel vs. spectroscopic imaging, ratios vs. 
single metabolites, different echo times, combined metabolites vs. individual), 
certain metabolites are emerging as important prognostic indicators in paediatric 
brain tumours, especially choline, lipids and myo-inositol. Larger studies are 
needed with consistent protocols, to investigate the relationships currently in the 
literature, and provide stronger evidence as to the value of these spectral 
biomarkers. Absolute quantitation using a water reference spectrum, short echo 
time spectroscopy and robust quantitation software which allows the determination 
of individual metabolite concentrations (such as GPC, PCh, Glu, Gln) will aid this 
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investigation.  Furthermore, 1H MRS at 3T would enable better distinction between 
Glu and Gln (117), and 31P MRS can be used to distinguish between GPC and 
PCh (118).  
 
5.5. CONCLUSION 
 
This study has investigated a large cohort of patients with low grade brain tumours 
over a long time period with respect to progression-free survival (PFS) and 
sequential spectral profile changes. High mIns and GPC and low PCh were found 
to be indicators of good prognosis. Follow-up MRS showed that patients with 
stable disease had a significant decrease (between pre-treatment and subsequent 
MRS) in lipids, macromolecules, PCh and Ala or no change in spectral profile, 
depending on the treatment group. Patients who progressed were found to have a 
significantly higher Gln on the second MRS (prior to prognosis) compared to the 
pre-treatment MRS, suggesting that Gln may be an earlier indicator of disease 
status than conventional imaging and clinical characteristics. This study therefore 
provides further evidence for the ability of certain metabolites to predict prognosis, 
focusing on low-grade gliomas.  
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CHAPTER 6 
 
CORRELATION BETWEEN HISTOLOGICAL FEATURES AND METABOLITE 
CONCENTRATIONS FROM IN VIVO 1H MRS IN PAEDIATRIC BRAIN 
TUMOURS 
 
6.1. INTRODUCTION  
 
Advances in Magnetic Resonance Imaging (MRI) and functional imaging including 
Magnetic Resonance Spectroscopy (MRS) in recent years mean there is a wide 
range of information available from non-invasive techniques. Thus, there is a need 
to determine how biomarkers obtained using these techniques relate to established 
tumour markers. 
 
The advent of new treatment protocols including agents directed against 
neoangiogenesis and gene therapy has increased the urgency for new 
methodologies of non-invasive characterization of tumours. The ability to develop 
non-invasive techniques, however, depends heavily on understanding the biology 
of the tumours and the correlation of this to the imaging tools we use. Magnetic 
resonance spectroscopy has been used increasingly for the characterization of 
brain tumours and provides valuable information which aids diagnosis, prognosis 
and treatment monitoring. Therefore, understanding the effects of features like 
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proliferation and vascularity and events like apoptosis and necrosis on the MRS 
spectra is imperative.   
 
This study was designed to test several hypotheses, based on current evidence in 
the literature on the role of specific metabolites and previous correlation studies, 
aiming to establish new metabolic correlates or confirm correlations from other 
small studies. A number of metabolites have already been studied with 1H MRS 
and their clinical and biological significance and relationship to important cell 
processes investigated to variable degrees. However, most studies have been 
performed using long echo time spectroscopy, which does not allow the 
quantitation of some metabolites which have biological and clinical importance, and 
there is very limited data from paediatric patients.  
 
The metabolites which have been investigated in previous research include choline 
(Cho), lipids, taurine (Tau), lactate (Lac) and N-acetyl-aspartate (NAA). The 
hypotheses we aim to test include the relationship between choline-containing 
compounds and Ki67 proliferation index, cellular atypia and mitosis. Choline has 
been linked to nuclear density (119), Ki67 proliferation index (58, 112) and nuclear 
shape (119, 120), and suggested as a marker of rapid cellular proliferation and 
tumour aggressiveness (65). Furthermore, the relationship between 
lipids+macromolecules and apoptosis, necrosis, cellular atypia, and mitosis will be 
investigated in this work.   Lipids have been linked to apoptosis (121, 122) and 
necrosis (28, 123), as well as Ki67 (119). Tzika et al. suggested that choline and 
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lipid mapping have value in tumour grading of glial tumours (123). Astrakas et al. 
showed normalized choline and lipids and/or lactate at 1.3ppm to be independent 
predictors of tumour grade (higher in high-grade tumours) (74). Furthermore, the 
importance of lipids and choline in the assessment of paediatric brain tumours is 
emphasized in the work by Marcus et al., which showed that choline, lipids and/or 
lactate (L), choline/NAA and choline+0.1L were significantly higher in non-survivors 
compared to survivors, and Cho+0.1L was the only independent predictor of 
survival(81).    
 
The correlation between taurine and apoptosis will be investigated, as  Moran et 
al.(124) and Lang et al (125)  have shown taurine to possibly be involved in the 
process of cell shrinkage in apoptosis. Several metabolites detected by 1H MRS in 
paediatric brain tumours in vivo are involved in energy metabolism, and interest in 
these has been increasing. One of the cellular metabolism alterations that features 
prominently in current research is increased aerobic glycolysis or the «Warburg 
effect» (126, 127).  During glycolysis, pyruvate is converted to lactate and alanine 
(in different ratios depending on organ type). Lactate has been suggested as an 
indicator of tumour metabolic activity in rat gliomas (128), but others do not agree 
(65, 129). Terpstra et al. (128) found a putative perfusion threshold above which 
tumour lactate was independent of haemodynamic and histologic factors (tumour 
blood flow, necrosis, inflammatory cell infiltrate). This supported the hypothesis that 
high lactate in most tumours is related to high glycolytic activity of viable neoplastic 
cells with adequate perfusion. Furthermore, lactate can be produced by anaerobic 
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glycolysis in degenerating/necrotic cells. Peet et al. (65) found higher lactate in 
localized compared to metastatic (high proportion of metabolically active cells) 
paediatric medulloblastomas and suggested this was due to anaerobic stress in the 
localized tumours. Kugel et al. did not find a correlation between lactate level and 
histologic tumour grade (129). Lactate is also present in cysts (130). In this study 
lactate and its relationship to necrosis, tumour architecture and vascularity will be 
investigated.   
 
Other metabolites of interest that are present in brain tumours and have been 
studied regarding diagnostic or prognostic value include myo-inositol and glycine. 
mIns, which can be detected reliably at short echo times, is a cerebral osmolyte 
and an astrocyte ‘marker’ (91). Glycine has been ignored in a lot of models that 
use MRS to discriminate between brain tumours, as it overlaps with myo-inositol 
and has a low concentration in normal brain (75). However, glycine has been 
reliably detected in paediatric brain tumours by Davies et al. (75) and shown to be 
significantly higher in high grade vs low grade tumours. Myo-inositol has been 
found to be higher in paediatric supratentorial pilocytic astrocytomas compared to 
cerebellar PAs, and optic pathway and thalamic tumours that progressed had 
significantly lower mIns at initial MRS compared to those with stable disease (66). 
Furthermore, tumour cells in astrocytic neoplasms stain intensely with antibodies to 
GFAP (131).  mIns and glycine will therefore be tested for their correlation with 
neoplastic and reactive glial elements and GFAP staining.  
 101 
 
 
A metabolite that has been used extensively in clinical studies as a putative 
neuronal marker (132) but has also caused most controversy regarding its origins 
is N-acetyl-aspartate (NAA). NAA is rarely seen in brain tumours, but significant 
amounts are seen in paediatric pilocytic astrocytomas, and it is still unclear 
whether it arises from tumour cells or infiltrating normal brain. This study aims to 
address this issue at a preliminary level, by testing its relationship with lesional and 
entrapped neuronal elements, as well as neoplastic and reactive glial elements and 
synaptophysin staining. Synaptophysin is a reliable marker of neuronal 
differentiation (133).  
 
Research on the specific relationships between metabolites detected with magnetic 
resonance spectroscopic techniques and histopathological features is still limited. 
Furthermore, work in this field is not always in agreement between different 
research groups, and results also need to be verified in vivo in paediatric patients.  
This study therefore aims at providing further evidence of the correlations of 
metabolites detected at short echo time with histopathological features in paediatric 
brain tumours. This is a small study to establish the existence of important 
relationships and the need for a larger, more detailed study.  
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6.2. MATERIALS & METHODS 
6.2.1. MRS 
 
MRS was performed routinely in children with brain tumours as part of the clinical 
imaging, at 1.5T, prior to any treatment (except stereotactic biopsy) at the 
Birmingham Children’s Hospital (BCH) from 2003 to 2009, and analysed 
retrospectively. The acquisition protocol involved using point-resolved 
spectroscopy (PRESS) localization for a single voxel. The voxel volume was either 
3.375cm3 or 8cm3 according to the size of the tumour.  A TE of 30ms was used for 
all patients. Some patients also had long echo time (TE=135) MRS (n=8). 
Repetition time was 1500-2000ms and 128 repetitions were used for 8cm3 voxels 
while 248 repetitions were used for 3.375 cm3 voxels. A water MRS was acquired 
for eddy current correction and as a concentration reference. Raw MRS signal data 
and voxel position images were transferred to a dedicated computer network. The 
signal was processed using LCModel software (version 6.2.0) (96), which 
determines metabolite concentrations by fitting the data to a linear combination of 
basis functions formed from individual metabolite spectra. Crammel-Rao Lower 
Bounds (CRLB) are also determined by LCModel, and these indicate the accuracy 
with which the metabolite concentrations have been estimated. Ethical approval 
was given for the study and written parental informed consent obtained. 
 
The spectra were reviewed individually to assess quality, and the ones failing the 
criteria set were excluded from the analysis. These criteria included signal-to-noise 
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ratio (S/N) ≥ 4 and full-width half-maximum (FWHM) ≤ 0.15ppm. Baseline stability, 
good phasing, adequate water suppression and absence of artifacts were 
assessed by inspection. The voxel positioning was also reviewed to ensure the 
voxel was positioned over tumour and did not include large amounts of normal 
brain or cyst. In addition, voxels needed to be at least 3mm away from lipid-
containing bone and scalp.   Statistical analysis was carried out using SPSS 
statistics software v.17.0 and p-values of <0.05 were considered statistically 
significant. The tests included two-tailed independent samples T-Tests and Two-
tailed Spearman-rank correlation tests.  
 
6.2.2. Segmentation 
 
For patients with significant amounts of cyst or ventricle in the voxel, segmentation 
of the MR images was performed and the metabolite concentrations adjusted 
accordingly (corrected metabolite concentration= concentration in voxel/active 
tumour fraction in voxel). The concentration of lactate was not altered in the three 
patients with cyst in the voxel (the tumour cysts contain lactate), but was altered for 
the patient with ventricle in the voxel.   
 
6.2.3. Histological review 
 
Histological review of H&E stained sections obtained at the time of biopsy or 
tumour resection for each patient was undertaken jointly with Dr. Brundler, 
 104 
 
 
consultant histopathologist at BCH, blind to the MRS results. The assessment was 
semi-quantitative, with each feature assigned a category. The H&E stained slides 
were assessed (as detailed in Table 1) for architecture and cellularity, presence of 
cellular atypia, mitosis, apoptosis and necrosis. Also recorded was the presence of 
neoplastic glial elements, reactive glial elements, entrapped neuronal elements, 
lesional neuronal elements, and vascularity. Ki67, GFAP and synaptophysin 
immunohistochemical stains were also reviewed were available.  
 
6.3. RESULTS 
 
27 children with low and high grade brain tumours were included in the study. The 
breakdown by tumour type (according to WHO 2007(104)) was: 9 
medulloblastomas,  5 pilocytic astrocytomas, 3 ependymomas, 2 atypical 
teratoid/rhabdoid tumours, 2 glioblastomas, 2 diffuse astrocytomas, 2 
dysembryoplastic neuroepithelial tumours, 1 pineoblastoma, 1 gliomatosis cerebri.  
 
The categories of all histopathological variables and the respective number of 
patients are shown in Table 1. Fig.1 shows some of the pathological parameters 
assessed in representative microphotographs. A summary of the statistically 
significant correlations described below is given in Table 2.  Ki67 proliferation index 
was tested for correlation with choline-containing compounds and there was a 
significant positive correlation between Ki67 and PCh (p= 0.031 c.c. = 0.442) and 
Ki67 and GPC+PCh (p= 0.006 c.c. = 0.544) but not GPC. A scatter plot of 
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GPC+PCh against Ki67 is shown in Fig.2C. Apoptosis was also assessed and 
correlation with lipids/macromolecules and taurine investigated. Apoptosis was 
assessed through the identification of characteristic nuclear changes, 
condensation, clumping and fragmentation of nuclei. This has been previously 
observed in medulloblastomas to correlate well with cleaved (activated) caspase 3, 
an immunohistochemical marker of apoptosis (65).  There was a significant 
positive correlation with lipids/macromolecules at 0.9ppm (p=0.001 c.c.= 0.581), 
1.3ppm (p=0.003 c.c. = 0.550), and 2.0ppm (p=0.005 c.c. = 0.520) and with Tau 
(p=0.014 c.c. =0.466). In addition, there was a significant correlation between 
lipids+macromolecules at 1.3 divided by those at 0.9ppm (p=0.001 c.c.= 0.584). 
Scatter plots of lipid at 0.9ppm and Tau vs. apoptosis are shown in Fig.2 (A, B 
respectively). Splitting cases by necrosis (present N=9, absent N=18) showed 
statistically significant positive correlations between apoptosis and 
lipids/macromolecules at 0.9 (p=0.004 c.c.=0.645), 1.3 (p=0.003 c.c.=0.656), 2.0 
(p=0.001 c.c.=0.718) and 1.3/0.9 (p=0.002 c.c.=0.667) ppm and Tau (p=0.002 
c.c.= 0.668) for the group with no necrosis present.  
 
Necrosis was present in 9 patients as mentioned above but in 1 it was very 
localized and this patient was removed from the analysis of necrosis and 
lipids+macromolecules and lactate. A comparison (t-test) of the 2 groups of no 
necrosis (N=18) and necrosis present (N=8) with respect to the amount of 
lipids+macromolecules at 0.9, 1.3 and 2.0ppm and lactate found no statistically 
significant differences. However, long TE lipids+macromolecules at 0.9 (p=0.002), 
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1.3 (p=0.002) and 2.0 (p=0.004) ppm were found to be significantly higher in the 
group with necrosis (n=2) compared to without necrosis (n=6) (t-test). Lipids at 
1.3/0.9 did not show any significant difference. Apoptosis was not found to 
correlate with lipids/macromolecules at long TE using the Spearman-rank 
correlation test.  
 
Furthermore, the correlation between cellular atypia and choline compounds and 
lipids+macromolecules was investigated. There was a significant positive 
correlation between atypia and PCh (p=0.013 c.c. =0.472), GPC+PCh (p=0.014 
c.c. =0.468), lipids+macromolecules at 0.9ppm (p=0.023 c.c. =0.437), 1.3ppm 
(p=0.016 c.c. = 0.458), and 2.0ppm (p=0.002 c.c. = 0.561). A scatter plot of atypia 
vs. lipids+macromolecules at 2.0ppm is shown in Fig.2 D. Spearman-rank 
correlation showed statistically significant positive correlations between mitosis and 
PCh (p=0.004, c.c.= 0.543), lipids+macromolecules at 0.9 (p=0.006, c.c.= 0.520), 
1.3 (p=0.012, c.c.= 0.487),   and 2.0ppm (p=0.001, c.c.= 0.602)  but not with GPC 
or GPC+PCh.  
 
Lesional neuronal elements were assessed and tested for correlation with NAA 
and NAA+NAAG and found to have a statistically significant negative correlation 
with both (p<0.0001, c.c. = -0.708 for both). No significant difference in NAA or 
NAA+NAAG between patients with and without entrapped neuronal elements was 
found.  
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There was a significant positive correlation between neoplastic glial elements and 
mIns (p=0.024 c.c. =0.432) and a significant negative correlation with Gly (p=0.001 
c.c.= -0.584), Fig. 2 E and F respectively. mIns+Gly did not have a significant 
correlation. There was also a significant positive correlation between neoplastic 
glial elements and NAA and NNA+NAAG (p<0.0001 c.c.=0.719 for both). mIns, 
Gly, mIns+Gly, NAA or NAA+NAAG were not singificantly different (t-test) between 
groups where reactive glial elements were present or absent. There was a 
significant negative correlation between GFAP staining and Gly (p=0.003, c.c. = -
0.576) but no significant correlation with mIns.   
 
Vascularity and architecture of the tumours were tested for correlation with lactate 
but no significance was detected. Synaptophysin staining was also tested for 
correlation with NAA and NAA+NAAG but no significance was detected. It should 
be noted however that synaptophysin staining was not performed on 16 patients 
(could be assumed to be negative as not performed when not expected e.g. in glial 
tumours).  
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Table 1 Histopathological categories and respective number of patients (short TE     
              studies)  
Histopathological feature Categories Number of patients 
Ki67 <1% 7 
1-2% 2 
4-10% 1 
>10% 14 
Not performed  3 
Apoptosis None 4 
Very low or low 10 
Moderate 7 
Moderate to high or high 6 
Necrosis Present   9 (1 very localised) 
Absent 18 
Cellular Atypia None 3 
Very low or low 8 
Low to moderate or low focally 
moderate or moderate  
8 
High 8 
Mitosis None 7 
Very low or low 7 
Moderate  7 
High 5 
Indeterminate  1 (removed from analysis) 
Lesional Neuronal Elements  None 13 
Focally PNET-like 3 
Neuronal Rosettes 4 
PNET-type 7 
Entrapped Neuronal Elements Present  3 
Absent 24 
Neoplastic Glial Elements None 10 
Focally or entrapped 2 
Predominantly neoplastic glial  15 
Reactive Glial Elements Present  15 
Absent  12 
GFAP staining  Negative  2 
Very focal or reactive glial 6 
<10% 2 
10-50% 4 
>50% 11 
Not performed  2 
Vascularity Low 8 
Moderate 14 
High 3 
Indeterminate 2 
Architecture Solid 15 
Solid diffuse 6 
Solid occasionally microcystic 
or microcystic 
3 
Half solid half cystic  3 
Synaptophysin staining  Negative 1 
Scattered positive 
synapthophysin cells  
1 
Focally positive 3 
Positive 6 
Not performed  16 
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Fig.1 Representative microphotographs illustrating pathological parameters 
assessed semiquantitatively. A= Classical medulloblastoma (H&E, x40 original 
magnification) showing a high cellularity and high levels of apoptosis (*), B= 
Pilocytic astrocytoma (H&E, original magnification x20) showing a low cellularity, 
and a partly solid, partly cystic (*) architecture, C= Classical medulloblastoma with 
synaptophysin widely and strongly expressed in tumour cells D= Classical 
medulloblastoma with high Ki67 labeling (>50% positive), E= Pilocytic astrocytoma 
showing strong staining with GFAP 
 
 
A B 
C D 
E 
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Table 2. Summary of statistically significant correlations between histopathological 
features and metabolites detected by 1H MRS 
 
Feature  Metabolite  Correlation/t-test  p-value  
Ki67  PCh  +ve  0.031  
Ki67  GPC+PCh  +ve  0.006  
Apoptosis  Lip+MM  at 0.9, 1.3, 2.0, 
1.3/0.9 ppm  
+ve  0.001, 0.003, 
0.005, 0.001  
Apoptosis  Tau  +ve  0.014  
Necrosis  Long TE Lip+MM at 0.9, 1.3, 
2.0 ppm  
Higher - group with 
necrosis  
0.002, 0.002, 
0.004  
Cellular atypia  PCh  +ve  0.013  
Cellular atypia  GPC+PCh  +ve  0.014  
Cellular atypia  Lip+MM at 0.9, 1.3, 2.0 ppm  +ve  0.023, 0.016, 
0.002  
Mitosis  PCh  +ve  0.004  
Mitosis  Lip+MM at 0.9, 1.3, 2.0 ppm  +ve  0.006, 0.012, 
0.001  
Lesional 
neuronal 
elements  
NAA, NAA+NAAG  -ve  <0.0001  
Neoplastic  glial 
elements  
mIns  +ve  0.024  
Neoplastic glial 
elements  
Gly  -ve  0.001  
Neoplastic glial 
elements  
NAA, NAA+NAAG  +ve  <0.0001  
GFAP  Gly  -ve  0.003  
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Fig.2 Scatter plots of A) Mean concentration value for MM09+Lip09 vs Apoptosis, B) Mean concentration value for  
Tau vs apoptosis,    C)  Mean concentration value for GPC+PCh vs Ki67, D) Mean concentration value for 
MM20+Lip20 vs Atypia, E) Mean concentration value for mI vs Neoplastic glial elements, F) Mean concentration 
value for Gly vs Neoplastic glial elements. Error bars represent +/- 1 standard error 
Mean= mean concentration value, MM09+Lip09=lipids and macromolecules at 0.9ppm, Tau=taurine, 
GPC=glycerophosphocholine, PCh=phosphocholine, MM20+Lip20= lipids and macromolecules at 2.0ppm, mI=myo-
inositol, Gly=glycine   
Mean concentration values are in “institutional units” (referenced to water unsuppressed spectrum - described in 
Chapter 3). 
E F 
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6.4. DISCUSSION  
 
1H MRS has seen increasing use over the last years as a non-invasive tool for the 
characterization and monitoring of brain tumours. Although many studies have 
reported the relationship between metabolites and diagnostic groups, tumour 
aggressiveness and prognosis, few have addressed the relationship with 
histopathological features routinely assessed after biopsy or resection. This study 
has investigated the correlations between metabolites detected by in vivo 1H MRS 
and histological features such as apoptosis, necrosis, mitosis, atypia, glial and 
neuronal components and found important relationships. It should be noted, 
however, that there was no confirmation that the region biopsied corresponded to 
the exact location of the 1H MRS voxel. Ki67 positively correlates with choline, as 
does atypia and mitosis. Apoptosis correlates with lipids detected at short echo 
time, whereas necrosis correlates with lipids at long echo time. Furthermore, 
relationships relating to glial and neuronal tumour components have been 
established, such as the inverse correlation of neuronal components with NAA, a 
quite surprising result, and the positive correlation of mIns with glial elements.  
 
Choline is involved in membrane synthesis and reflects membrane turnover, and 
Cho elevation has been attributed to rapid cellular proliferation, as a result of 
increased mitosis, leading to an abnormal increase in metabolism and the 
destruction of cells (112, 119, 120, 134).  In a study by Nafe et al., nuclear density 
of grade II-IV gliomas was found to correlate positively with total choline at long TE, 
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and the proliferation index Ki-67 correlated positively with the lipid peak at 0.9ppm 
(119). Ki-67 did not correlate with the total choline peak in that study, as well as in 
the study by Gupta et al. (long TE MRSI of adult glioma patients measuring 
normalized choline)(135), but other studies found a positive correlation, which 
agrees with the results of this study (positive correlation between PCh and Ki67 
and GPC+PCh and Ki67); Tamiya et al.(112) found a positive correlation between 
total choline/Cr ratio and Ki67 and a negative correlation between NAA/Cho and 
Ki67 (15-68 years old, grade II-IV astrocytomas); Shimizu et al.(58) found a 
positive correlation between total choline measured semiquantitatively at long echo 
time MRS and Ki-67 in the homogeneous adult gliomas but not the heterogeneous 
ones; and Peet et al. found a positive correlation between total choline at short TE 
and Ki67 in medulloblastomas (65).  
 
A significant positive correlation was also found between Tau, lipids at 0.9, 1.3, 2.0, 
1.3/0.9ppm and apoptosis. Apoptosis is an active process of programmed cell 
death (124). Some characteristics of apoptosis include cell shrinkage, 
fragmentation and condensation of nuclear material and cytoplasm vacuolization 
(124, 136). MAS and histopathological analysis performed by Opstad et al. found 
taurine to significantly correlate with apoptotic cell density in necrotic and non-
necrotic biopsies (137). In a study by Moran et al. a model of apoptotic death in 
cultured cerebellar granule neurons was used, and the basal release of [3H] 
taurine from cells started to increase after 3 days up to a maximum at 5 days. At 5 
days, the cell morphology of the neurons displayed characteristics of apoptosis, 
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including marked soma shrinkage (124). This was preceded by caspase induction 
and chromatin condensation, which are apoptotic death markers (124). However, 
the nuclear pool of taurine could also be contributing to the decrease in cell volume 
(124). Lang et al (125) loaded Jurkat human T-lymphocytes with [3H]taurine and 
induced apoptotic cell death by triggering the Fas(CD95) receptor with monoclonal 
crosslinking antibody. This led to a release of taurine of 60% of cellular taurine in 
90 min. The release coincided and presumably contributed to the cell shrinkage 
typical of apoptotic death, and preceded DNA fragmentation.  
 
Lipids detected by MR spectroscopy have been linked to necrosis or apoptosis (28, 
123). Tzika et al. showed microscopic necrosis in 11 paediatric patients with low 
total choline and high lipid and/or lactate  signal with MRSI at an echo time (TE) of 
65ms, and the spectra were assumed to correspond to areas of high neoplastic 
potential (28). Tzika et al. suggested that choline and lipid mapping have value in 
tumour grading of glial tumours (123). In another study, paediatric high-grade 
tumours were distinguished from low-grade ones using normalized choline and 
lipids from MRSI, with high-grade tumours having significantly higher choline and 
lipids. Also, lipid peaks positively correlated to percent necrosis (16).  Astrakas et 
al. showed normalized choline and lipids and/or lactate at 1.3ppm to be 
independent predictors of tumour grade (higher in high-grade tumours) (74). 
Furthermore, the importance of lipids and choline in the assessment of paediatric 
brain tumours is emphasized in the work by Marcus et al., which showed that 
choline, lipids and/or lactate (L), choline/NAA and choline+0.1L were significantly 
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higher in non-survivors compared to survivors, and cho+0.1L was the only 
independent predictor of survival(81).     
 
Blankenberg et al. found a directly proportional relationship between the ratio of the  
methylene (CH2) resonance at 1.3ppm to the methyl (CH3) resonance at 0.9ppm 
and the percentage of apoptotic lymphoblasts in doxorubicin-treated Jurkat T-cell 
acute lymphoblastic leukaemia cultures in vitro (122).  Hakumaki et al have 
investigated early biochemical and biophysical events taking place during GCV-
induced apoptosis of experimental gliomas (BT4C gliomas in rats), and found an 
association with accumulation of polyunsaturated fatty acids (PUFAs) detected by 
1H MRS in vivo at an echo time of 20ms (121). 
  
In vivo 1H MRS detected lipids are associated with tumour aggression and Opstad 
et al.(138) studied adult human astrocytoma biopsy samples with magic angle 
spinning 1H MRS at TE=50ms and suggested that the ~1.3ppm lipid signal 
correlated strongly with the number of Nile Red-stained lipid droplets and the 
formation of lipid droplets precedes necrosis.  In a study by Zoula et al. of C6 rat 
glioma, the mobile lipid signal at 1.3ppm at TE=136ms was suggested to arise 
mainly from lipid droplets in necrosis (139).  In humans, this mobile lipid signal has 
been observed mainly on NMR spectra of necrotic brain tumour biopsies(139, 140) 
and in metastasis (129) and high grade gliomas (141). However, our results did not 
show a significant difference between lipids or lactate in necrotic and non-necrotic 
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tumours, possibly due to the small numbers especially in the necrotic group (n=8). 
Another explanation is that lipids detected at short echo times relate to apoptosis 
and those detected at long echo times to necrosis. To investigate this, the long TE 
spectra of the patients in the study were analysed where available (N=8). 
Interestingly, lipids at 0.9, 1.3 and 2.0 ppm were significantly higher in patients 
where necrosis was present. Apoptosis did not correlate with long TE lipids.  
 
Other histological features studied included atypia and mitosis, and both were 
found to have significant correlations with PCh and lipids at 0.9, 1.3 and 2.0ppm 
(atypia also correlated with total choline). This may have been expected as choline 
and lipids are known to be higher in more aggressive tumours (16, 81), and a high 
degree of atypia and mitosis are also features of aggressiveness.  
 
There are several metabolites detected by 1H MRS in paediatric brain tumours in 
vivo which are involved in energy metabolism, and interest in these has been 
increasing. Molecular imaging has seen great advances in recent years (18F-FDG 
PET, SPECT, MRS) and research into the activation of certain oncogenes and 
alterations of cellular metabolism has been expanding (126). One of the cellular 
metabolism alterations that features prominently in current research is increased 
aerobic glycolysis or the «Warburg effect» (126, 127).   During glycolysis, pyruvate 
is converted to lactate and alanine (in different ratios depending on organ type). 
Golman et al. showed significantly higher lactate in implanted P22 tumours in rats 
compared to normal tissue, after injection of hyperpolarized 13C-pyruvate (127).  
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Spectroscopic studies have shown elevated lactate in the brain in conditions such 
as ischaemia (142) and brain tumours (129). Lactate has been suggested as an 
indicator of tumour metabolic activity in rat gliomas (128), but others do not agree 
(65, 129). Our results did not find a correlation between lactate and necrosis or 
vascularity. It should also be noted that lactate is found in cysts, and Chang et al. 
showed that lactate is observed in a variety of intracranial cysts and there tends to 
be a higher lactate peak in high-grade gliomas (130). In this study, tumour 
architecture did not correlate with lactate. 
 
Another question we attempted to address at a preliminary level in this work has 
been the origin of NAA, a matter of much controversy which has been studied 
extensively so far. It is especially pertinent when looking at pilocytic astrocytomas, 
as they normally show relatively high levels of NAA, even when no normal brain is 
contained within the voxel and there is a debate as to whether it arises from the 
tumour itself or from surrounding entrapped normal brain. Looking at the histology 
slides, we found a significant positive correlation between NAA and neoplastic glial 
elements and a significant negative correlation between NAA and lesional neuronal 
elements. This result suggests that the NAA seen in pilocytic astrocytomas may 
actually arise from the tumour itself, and previous observations in our lab also 
suggest that the NAA seen cannot be explained by voxel contamination. Lazareff 
et al. (67) also observed NAA in paediatric low grade astrocytomas that could not 
be explained by partial volume effects. O-2A progenitors which contain NAA (143) 
are primitive bipotential cells which can give rise to oligodendrocytes or type-2 
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astrocytes, and some low grade astrocytomas express antigens consistent with 
type-2 astrocytic lineage (144). 
 
Myo-inositol has been found to correlate positively and Gly negatively with 
neoplastic glial elements. This is as expected as mIns is known to be relatively 
high in glial tumours (astrocyte ‘marker’ (91)) and glycine is known to be higher in 
high grade tumours (75). In our study, the glial tumours were mainly low grade. 
This also explains the negative correlation between glycine and GFAP staining. 
mIns was not found to correlate with GFAP, although they are both considered to 
be gliosis markers, and this agrees with the results of another study by Oz et al. 
(145), who studied GFAP levels in CSF of patients with spinocerebellar ataxia type 
1 and their relationship to metabolites from different brain locations (TE=5ms, 4T).  
However, they found that the patients with the highest GFAP level had the highest 
mIns level in the vermis, which we did not observe in our results.   
 
6.5. CONCLUSION 
 
In summary, we have addressed all the principal histological features routinely 
assessed by histopathologists in the diagnostic process and found spectroscopic 
correlates for most, providing additional evidence for the use of in vivo 1H MRS as 
a non-invasive characterization tool in paediatric brain tumours. 
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CHAPTER 7          
PRELIMINARY STUDY OF IN VITRO NMR SPECTROSCOPY OF PAEDIATRIC 
PILOCYTIC ASTROCYTOMA CELL LINES  
 
7.1. INTRODUCTION 
 
Data presented earlier on suggests the presence of NAA in low grade gliomas, not 
explained by partial volume effects. This is in agreement with the observations of 
Lazareff et al.(67), and combined with the controversy in the literature surrounding 
the origins and functions of this amino acid, a preliminary study to investigate this 
was designed. This pilocytic astrocytoma cell line study also aims at describing the 
1H MR spectroscopic profile of the cells lines at a high magnetic field, and 
investigating the ability to detect subtle differences in tumour cells originating from 
histologically identical samples.  
 
N-acetyl-L-aspartate (NAA) is an amino acid that is present in the vertebrate brain 
(146). It is synthesized and stored primarily in neurons, but cannot be hydrolysed in 
these cells. Neuronal NAA is dynamic with a turnover of more than once per day, 
via extracellular fluids between neurons (anabolic compartment) and 
oligodendrocytes (catabolic compartment) (146). Oligodendrocyte amidohydrolase 
II hydrolyzes NAA liberated from neurons  into aspartate and acetate  
(amidohydrolase I activity in astrocytes also has a minor role) (146). Aspartate gets 
recycled back to form new NAA, and most of the acetate gets taken up and 
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metabolised by oligodendrocytes and astrocytes and lost from the NAA cycle(146). 
Other sources of brain NAA are mast cells, astrocytes, microglia, CSF, and the 
intravascular compartment, all of which (including ECF and oligodendrocytes) 
comprise a negligible component of NAA under normal conditions (146).  It is a 
major brain metabolite which is being increasingly used in clinical and experimental 
MRS studies as a putative neuronal/axonal marker (132, 147).  
 
Abnormalities of NAA resonance intensity have been found in various cerebral 
disorders, from brain tumours to stroke, inborn genetic abnormalities and 
neurodegenerative disorders including multiple sclerosis (143, 147). However, to 
interpret the changes in NAA seen in vivo, its cell type specific localization and 
function need to be known (132, 143).  A lot of work has been done on this 
metabolite, and it has been suggested that it may be a specific constituent of 
neurons in the mammalian brain (132, 143) and is synthesized by mitochondria 
(132). Experiments have involved causing damage to neurons and observing the 
decrease in NAA (143), immunocytochemical studies using antibodies to NAA 
showing that it was discretely localized in a substantial number of neurons 
throughout the rat CNS (although many neurons remained unstained (148, 
149))(132, 143). Additional evidence to support the neuronal localization of NAA 
has come from its absence in cultured cortical astrocytes (143), its undetectable or 
very low levels in meningiomas and astroglial tumours and its relative abundance 
in medulloblastomas (132, 143). NAA has therefore been thought of as a marker of 
neuronal loss or viability (132, 143). 
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However, NAA has been reported to decrease reversibly in various disorders, 
suggesting that the initial decrease was not due to neuronal or axonal loss. 
Examples of spontaneous or treatment-related reversibility in NAA decrease 
include multiple sclerosis, mitochondrial diseases, acquired immunodeficiency 
syndrome, temporal lobe epilepsy and amyotrophic lateral sclerosis (147). 
Temporal studies of multiple sclerosis and mitochondrial encephalopathy with lactic 
acidosis and stroke like episodes and hypothyroidism have shown reversible 
changes in NAA in vivo (132). These changes are related with an underlying 
pathology which involved a dysfunction of myelination. It is therefore paradoxical to 
consider NAA to be neuron-specific whilst in the early stages of disease there is 
preservation of relatively normal grey matter but degeneration of myelin (132). 
Thus, the possibility of a contribution to the NAA signal by oligodendrocytes is 
raised (responsible for myelination of neurons in the CNS) (132).  Other 
explanations have been proposed in conditions where there is reversible loss of 
NAA, including axonal recovery after an insult to the neuron which does not 
destroy it completely, consolidation of surviving brain tissue after neuronal death in 
cortical atrophy, presence of other metabolites with spectra resonances in the 
same region, fluctuations due to osmolarity since NAA is a reversible cerebral 
osmolyte, and slow NAA resynthesis  (91). 
 
In addition, although NAA is accepted as a marker of neuronal viability, its 
presence in other major cell types in not completely unexpected. It has been 
shown in rat brain extracts to increase rapidly to adult levels from day 10 to 20 of 
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life, which is the time of active myelination in this animal (132). Human foetal and 
child brains also show an increase in NAA at a time when myelination is at its 
maximum. The neuronal cell density in the cerebral cortex decreases with dendritic 
maturation, therefore an increase in NAA with age may reflect a contribution from 
cells other than neurones (132). Furthermore, experimental work using isolated 
nonsynaptic brain mitochondria has shown that partial inhibition of the 
mitochondrial respiratory chain results in partial decrease in NAA synthesis, 
meaning that an impairment of mitochondrial function may contribute to a decrease 
in NAA without cell death (132). 
 
Urenjak et al. found NAA in cultures of purified neurons, O-2A progenitors (higher 
than in cerebellar granule neurons) and immature oligodendrocytes, but not mature 
oligodendrocytes, purified meningeal cells or purified cortical astrocytes (from 
neonatal rats) (143). Therefore, at least in the developing brain, there is a 
possibility that a major contribution of NAA comes from oligodendrocyte precursors 
rather than being solely due to neuronal populations (143). However, it would seem 
paradoxical that immature oligodendrocytes have less NAA and mature 
oligodendrocytes none compared to O-2A progenitors, if NAA is involved in 
myelination. An explanation for this by Urenjak et al. is that lipid synthesis is so 
extensive that it depletes newly produced NAA in oligodendrocytes (143).However, 
more recently, studies on oligodendrocyte biology revealed the requirement for 
ciliary neurotrophic factor (CNTF) to promote the generation, maturation and 
survival of oligodendrocytes in vitro.  Bhakoo and Pearce used this new cell 
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cultivation procedure (cells from 7-day old rats) and found that mature 
oligodendrocytes actually do express NAA in vitro (132).  Bhakko and Pearce (132) 
found NAA in the O-2Α progenitors although less than previously published data, 
and in immature (similar levels) and mature olidendrocytes (both in CNTF-treated 
and untreated cells, higher in treated). The levels of NAA in mature 
oligodendrocytes were comparable to those seen in various neuronal cultures 
(cerebellar granule neurons, cortical neurons, dorsal root ganglion neurons). 
However, it is uncertain whether these NAA levels are the same in the individual 
cell types in vivo. The number of live oligodendrocytes was significantly lower in 
the untreated culture, but this does not account for the absence of NAA in the 
study by Urenjak et al (143), although NAA in untreated cultures was less.    
 
The function(s) of NAA remain unclear and there have been many proposed roles 
for it (132). The possibility that it donates acetyl groups for lipid synthesis and 
especially myelination is interesting when combined with the results from studies 
showing NAA in oligodendrocyte precursors and oligodendrocytes (132, 143). 
Other proposed roles range from the metabolism of specific brain fatty acids to ion 
balance and neuromodulation, regulator of protein synthesis, and storage from of 
acetyl-CoA or aspartate (132, 147). Baslow suggests that NAA may have several 
functions in the CNS, but of particular importance is its osmoregulatory role, and in 
this it may be the primary mechanism for the removal if intracellular water from 
myelinated neurons, against a water gradient (146). An interesting finding is that 
the NAA metabolic system may not be required for brain function at all, and 
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neurons can form synaptic connections without it and oligodendrocytes can still 
produce myelin and form a sheath around axons in its absence (146). The 
macroscopic concentration of NAA depends on the fluxes of synthetic and 
degradation pathways, cellular density and brain water content and distribution 
(147). A decrease in NAA could be due to an increase in extracellular water or CSF 
content in the voxel (can be corrected during analysis). Even when tissue NAA 
content is reduced and is attributed to neuronal or axonal dysfunction or loss, it is 
not known whether this is due to an irreversible loss of cells or a potentially 
reversible metabolic process (147).   
 
Care is needed when extrapolating in vitro cellular data to in vivo and to human 
brains, as many factors such as cell-cell interactions cannot be mimicked in culture 
(132). Also, quantitative conclusions about NAA in the intact brain are difficult to 
draw from the work of Urenjak et al. (143) as the cerebellar granule cells were 
cultured from 7-dat old rats (prior to the rapid increase in NAA), and also the 
proportions of the various cell types in vivo are unknown. If the proportion of O-2A 
progenitors and immature oligodendrocytes is very small, then NAA may be a 
useful neuronal marker as that would be the major source of it. In addition, there 
are many similarities between O-2A progenitors and neurons, although they are 
two functionally very distinct cell types (143). 
 
Additional evidence for the presence of NAA in non-neuronal cells comes from the 
study of Canavan’s syndrome, a rare autosomal recessive leukodystrophy that 
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affects newborn infant and young children (132). There is a deficiency of N-
acetylaspartoacylase, which cleaves NAA to acetate and aspartate and is therefore 
the only disease where NAA increases. This disease involved spongy 
degeneration of white matter due to vacuolation and demyelination, but no 
abnormality of neurons (132). The increase in NAA is clearly not due to an 
increase in neuronal density (147).  
 
This study aims to investigate whether 1H NMR of three paediatric pilocytic 
astrocytoma cell lines, one from a ‘typical’ tumour, one from a metastatic tumour at 
presentation and one from a recurrence,  can detect differences between them, 
even though the tumours are histologically identical. Furthermore, the presence or 
absence of NAA in these cell line spectra will be investigated, to provide some 
preliminary evidence as to its origins in in vivo 1H MRS of paediatric pilocytic 
astrocytomas.  
 
7.2. METHODS 
7.2.1. Cell Culture 
 
Three cell lines were used in this work, namely PA1, PA3R and PA7. PA1 was 
derived from a paediatric pilocytic astrocytoma which was metastatic at 
presentation (age=2 yrs, cerebellar), PA3R from a recurrence of a paediatric 
pilocytic astrocytoma (age=2yrs, cerebellar), and PA7 from a ‘typical’ paediatric 
pilocytic astrocytoma (age=7 yrs, thalamic). The cells were cultured using standard 
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protocol in Dulbecco's Modified Eagle Medium (D-MEM) (low glucose), which 
contained 1000 mg/L glucose, 4mM L-glutamine and 110 mg/L sodium pyruvate 
and 15% FBS (PAA, UK).  
 
7.2.2. Cell harvest 
 
The cells were harvested at a confluence of about 90% and 24 hours after a final 
medium change. The flask to be harvested was washed 3x with cold PBS and the 
cells scraped off into a cryovial. This was centrifuged at 250g for 6min+brake, the 
supernatant was discarded and the cryovial dropped in liquid Nitrogen prior to 
storage at -80°C. The time from removing the flask from the incubator and 
dropping the cryovial into liquid Nitrogen did not exceed 15 min.  
 
7.2.3. Whole cell sample preparation 
 
The cells were thawed, 600μl D2O was added to resuspend the cell pellets, 
followed by grinding the sample approximately 80 times on ice. This was 
transferred to an eppendorf and stored at -80°C.  
 
7.2.4. Extraction  
 
20-40 million cells were used for each Nuclear Magnetic Resonance (NMR) 
spectroscopy sample. The cells were thawed, 85μl of ice cold distilled water and 
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400μl of ice cold methanol were added. The mixture was grinded approximately 80 
times in a  glass grinder on ice, transferred into a 1.5ml eppendorf tube and put on 
ice, then sonicated at a tune value of 8 (power=5W) for 10-15s (Misonix, USA). 
Following this, 200μl ice cold distilled water and 200μl ice cold distilled chloroform 
were added and the sample vortexed at high speed for 10-20s. The sample was 
placed on ice and put on a shaker for 20-30min at 20rpm, then centrifuged in a 
cold centrifuge at 2000g for 5 min at 4°C (Hettich Zentrifugen, Germany). The 
upper water phase and the lower chloroform phase were put into new separate 
eppendorfs (e1, e2), leaving the protein (middle phase) in the original eppendorf 
(e3). 200μl of ice cold chloroform was added to the upper water phase (e1) and the 
protein (e3) and these were vortexed for 10-20s and then centrifuged as before. 
The upper phase of each was transferred to a new eppendorf (e4) and the lower 
phase of each to e2. The protein was left in e3 and stored at -80°C. The water 
phase was split into two equal amounts (e4 and e5) and vacuum centrifuged 
(Eppendorf Concentrator 5301, Germany) to dry, then transferred to -80°C for 
storage. The organic phase was left in a fume hood overnight to dry and then 
transferred to -80°C for storage.  
 
7.2.5. NMR sample preparation  
7.2.5.1. Whole Cells  
 
5μl of 10mM TMSP was added to the sample which was then vortexed for 10s and 
transferred to a Norsell s600 NMR tube. 
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7.2.5.2. Extracts- Water sample 
 
600μl of D2O was added to the sample (half of sample in eppendorf e4), which was 
then vortexed for 10s and combined with the sample in e5. 5μl of 10mM TMSP was 
added as a reference compound and the sample vortexed for 10s, then the sample 
was transferred to an NMR tube and spun manually.  
 
7.2.6. NMR protocol 
 
There were 4 repeats for PA1 and PA3R and 3 repeats for PA7 extracts. 1 repeat 
of PA1 was removed from the analysis as it was contaminated. 3 repeats were 
collected for each cell line for whole cell NMR.  
 
A Varian 600-MHz (14.1 T) vertical bore spectrometer using an HCN probe was 
used to record the 1H NMR spectra of cell extracts and whole cells suspended in 
D2O. The probe temperature was set to 20°C. Tuning and matching and 
presaturation pulse frequency were optimized for each sample. A standard pulse 
and acquire sequence was used, consisting of a single 90° pulse preceded by one 
second of water presaturation. The acquisition was of 16K complex points at a 
sampling frequency of 7200Hz. The number of scans used varied according to the 
signal-to-noise ratio of each sample (256-1024).  
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Spectral processing and Principal Component Analysis were performed by Dr. 
Martin Wilson. TARQUIN (150) software was used for processing the in vitro 
spectra.   
 
7.3. RESULTS 
 
The three paediatric pilocytic astrocytoma cell lines were grown successfully, and 
microphotographs of cells in culture from each cell line are shown in Fig.1. Whole 
cell NMR and cell extract NMR of the 3 cell lines showed reproducible results and 
no NAA in any of the samples. Interestingly, we observed a resonance at 1.9ppm 
which has been assigned to acetate in all the samples. MAS of pilocytic 
astrocytomas (performed previously in our lab, results not shown (113, 151)) also 
showed acetate and very little NAA believed to arise from normal brain in the 
biopsies. Fig.2 shows spectra obtained with each method (A= ‘typical’ pilocytic 
astrocytoma cell extract NMR, B=‘typical’ pilocytic astrocytoma whole cell NMR). In 
addition, we have shown that 3 cell lines of the same tumour type (1 ‘typical’, 1 
recurrence and 1 metastatic at presentation) can be discriminated very well using 
NMR and principal components analysis. PC2 vs. PC1 plots of the cell extract and 
whole cell data are shown in Fig.3. The whole cell data was both the easiest to 
collect and the most reproducible.  
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Fig.1 Microphotographs of cells in culture A. PA1, paediatric pilocytic astrocytoma 
metastatic at presentation cell line, passage 15, magnification x10; B. PA3R, 
recurrence of a paediatric pilocytic astrocytoma cell line, passage 19, magnification 
x10; C. PA7, ‘typical’ paediatric pilocytic astrocytoma cell line, passage 8, 
magnification x10 
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B 
Fig.2 NMR Spectra of ‘typical’ paediatric pilocytic astrocytoma cell line. A. Water 
phase extract B. Whole cell sample   
Ace= acetate, Ala= alanine, Cho=free choline, Cr= creatine, Gln=glutamine, 
Glu=glutamate, Gly=glycine, GPC=glycerophosphocholine, Lac=lactate, 
mIns=myo-inositol, MMs= macromolecules, PCh=phosphocholine, 
PEth=phosphoehtanolamine, Scyllo= scyllo-inositol, Tau=taurine  
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Fig.3 Plots of Principal Component (PC) 2 vs. PC1 from a Principal Component 
Analysis (PCA) of the NMR spectra from the 3 paediatric astrocytoma cell lines A. 
Water phase extract spectra B. Whole cell spectra. PA1= paediatric pilocytic 
astrocytoma metastatic at presentation, PA3R= recurrence of a paediatric pilocytic 
astrocytoma, PA7= ‘typical’ paediatric pilocytic astrocytoma  
A 
B 
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7.4. DISCUSSION 
 
This study demonstrates that 1H NMR has the ability to detect subtle differences 
and discriminate between three paediatric pilocytic astrocytoma cell lines (‘typical’, 
metastatic and recurrence). The in vitro 1H NMR spectra of the pilocytic 
astrocytoma cell lines demonstrate the characteristic features of pilocytic 
astrocytomas in vivo. There is a very low Cr, relatively high Cho and myoinositol, 
and lipids (in whole cells) and lactate can be detected. It is of note that in contrast 
to pilocytic astrocytomas in vivo, there tends to be more PCh than GPC in the in 
vitro spectra; this is also the case in metastatic astrocytomas in vivo. Furthermore, 
we have shown that there is no NAA in these cell lines, which if present, would 
explain the presence of the NAA seen in vivo in these tumours, thus raising the 
possibility that the singlet at 2.02ppm in vivo is due to another molecule. However, 
further work is needed to clarify the origins of NAA seen in vivo in paediatric 
pilocytic astrocytomas.  
 
The spectra from the cultured cells have shown essentially no NAA in any pilocytic 
astrocytomas, but significant amounts of acetate (singlet at 1.9ppm). Therefore, 
our hypothesis is that the resonance around 2.0ppm in pilocytic astrocytomas 
arises from acetate (or acetate plus NAA when normal brain is contained within the 
voxel), but it cannot at present be resolved in in vivo MRS at 1.5T. This may 
provide a better biomarker for pilocytic astrocytomas, but further work is needed. 
Acetate is a simple molecule with a single CH3 group which gives a singlet at 
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1.9ppm (152). It  may be an artifact of sample preparation (152), however it was 
present in the whole cell NMR samples as well, meaning that this is probably not 
the case in our work. It has been observed to be higher in brain tumours (152). An 
interesting point is that it gets shifted downfield at lower pH (152), which may make 
it even more difficult to observe in in vivo MRS as it merges with the resonance 
from NAA and lipids at around 2.0ppm. This is of particular interest in pilocytic 
astrocytomas, as they often contain significant amounts of lactate, which may 
indicate a more acidotic state.  
 
7.5. CONCLUSION 
 
In conclusion, it has been shown that 1H NMR has the ability to detect differences 
between cells from histologically identical tumours, providing further evidence for 
its use in characterization and prognostication of paediatric brain tumours, as one 
of the tumours was metastatic at presentation and the other was a recurrence. 
Furthermore, from this preliminary work, it is suggested that the resonance 
assigned to NAA in in vivo 1H MRS in pilocytic astrocytomas may actually 
correspond to a different molecule, acetate being a possibility. However, the 
acetate present in the cell lines could be a result of the culturing and harvesting 
process, and needs further investigation. 
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CHAPTER 8 
MAGNETIC RESONANCE SPECTROSCOPIC IMAGING- CLINICAL CASE 
STUDIES 
 
8.1. Case Study 1 
 
The following case study demonstrates the value of 1H Magnetic Resonance 
Spectroscopic Imaging (MRSI) in the assessment of large heterogeneous lesions 
with areas demonstrating varying aggressiveness and potential for progression.  
 
The patient is a girl who presented at the age of 4 years with a reduced use of the 
right hand. An MRI in March 2008 revealed a left thalamic lesion going 
contralateral and extending into deep white matter of the left cerebral hemisphere. 
After stereotactic biopsy from the middle of the left thalamic lesion (most 
hyperintense part of lesion on T2-weighted MRI), a diagnosis of diffuse fibrillary 
astrocytoma WHO grade II was made. Single voxel 1H Magnetic Resonance 
Spectroscopy (MRS) of the left thalamic lesion pre-treatment, shown in Fig.1, 
showed decrease N-acetyl-aspartate (NAA) and Creatine (Cr) at 2.02 and 3.0ppm 
respectively, and increased glycerophosophocholine+phosphocholine (Cho) at 
3.2ppm, myo-inositol (mIns) at 3.6ppm and lipids+macromolecules, suggestive of a 
tumour, although not entirely typical of diffuse astrocytomas on qualitative review 
(Cho and NAA expected to be higher). However, the possibility of a different 
histology in the area in the left cerebral hemisphere was raised (MR image in 
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Fig.2). Short Echo Time (TE, 30ms) MRSI performed in May 2008,  showed Cho to 
be increased more in the area in the left cerebral hemisphere adjacent to the 
biopsied lesion, rather than at the site of the biopsied lesion, and mIns to be higher 
in the left thalamic lesion. The Cho and mIns maps, co-registered on the MR 
images, are shown in Fig.3. Care should always be taken when interpreting 
chemical shift imaging (CSI) metabolite maps since they are prone to artifacts. One 
property of the PRESS CSI method, known as the chemical shift artifact, leads to 
the displacement of the localisation volume for each metabolite depending on their 
chemical shift. In MRSI, the volume of interest is excited (subject to chemical shift 
displacement) but then phase encoding is used as a separate means of signal 
localization (negligible chemical shift displacement). Thus, the voxels around the 
outer edge of the volume of interest can suffer from chemical shift displacement 
artifacts (93). At 1.5T the size of the chemical shift artifact is usually small by 
comparison with the nominal voxel size, and the region of abnormality is sufficiently 
large in the case presented that the findings should not be greatly affected by this 
problem (93). Furthermore, the metabolite maps in this case were predictive of 
disease progression demonstrating their utility. Individual spectra from the MRSI 
grid, representative of the 2 areas under discussion, are shown in Fig.4. High 
choline has been shown to be a bad prognostic indicator (78-80). Castillo et al. (57) 
found a trend toward higher  mIns/Cr in low-grade cerebral astrocytomas 
compared to anaplastic astrocytomas and glioblastoma multiforme in a study of 
short echo time 1H MRS in children and adults.  
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Fig.1 Pre-treatment MRS of left thalamic lesion. NAA= N-acetyl-aspartate, Cr= 
Creatine, Cho=choline (glycerophosophocholine+phosphocholine), mIns= myo-
inositol, MMs= macromolecules 
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Fig.2 T2-weighted MR image of tumour 
 
 
Fig.3 LEFT Choline (Cho) map, showing the highest level of Cho in the left 
cerebral hemisphere (red). RIGHT Myo-inositol (mIns) map, showing the highest 
level of mIns in the left thalamus (red).  
Left thalamus lesion, high T2 signal, site of biopsy 
Biopsied tumour in 
left thalamus 
Area suspicious of 
different (higher grade) 
histology in left 
cerebral hemisphere 
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Fig.4 MRSI spectra from the left thalamus (biopsied tumour) (ABOVE) and the 
adjacent left cerebral area of possible higher grade part of the lesion (BELOW). 
Ins=myo-inositol, Cho=choline, Cr=creatine, NAA=N-Acetylaspartate 
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Treatment with chemotherapy as randomised on LGG2 protocol (vincristine and 
carboplatin) with careful monitoring was started (April 2008). In September 2008, 
the MRI suggested tumour infiltration of the left hemisphere with possible 
progression. As there was also significant toxicity from chemotherapy, second line 
treatment with radiotherapy was undertaken, followed by an increase in tumour 
size and a subsequent improvement. In October 2009, the MRI showed diffuse 
disease progression in the left hemisphere, and treatment on oral temozolomide 
was started. After two courses, there was further disease progression, but as the 
patient was neurologically stable, treatment was continued.  Further disease 
progression was seen on MRI in April 2010, and oral etoposide was started. 
Clinical progression was confirmed in June 2010, and end of life palliative care 
started. The patient died in September 2010.  
 
Although a biopsy of the lesion in the left cerebral hemisphere was not performed, 
this area behaved in a more aggressive manner compared to the biopsied left 
thalamic lesion. The MRSI findings in this case were predictive of the worse 
prognosis of this lesion, as higher choline and lower mIns were found compared to 
the biopsied diffuse astrocytoma. If this finding is validated in large studies, it could 
provide tumour biopsy guidance and/or be a predictor of progression.  
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8.2. Case Study 2 
 
The following case demonstrates the value of MRSI in complex lesions which 
make single voxel spectroscopy (SVS) difficult, due to for example bleeding as in 
this case. MRSI can investigate many smaller voxels around the lesion, and still 
provide useful information, especially when the biopsy sample is small and the 
diagnosis difficult to make as in this case.   
 
This boy presented at 5 years of age, with a history of Neurofibromatosis type I 
(NF1) and progressive weakness of the left leg, then arm and face over a few 
weeks. An MRI showed a right thalamic lesion most consistent with low grade 
glioma, and an optic chiasm glioma. Single voxel short TE MRS performed at the 
time was difficult to interpret as there was only a small part of solid tumour in the 
voxel (Fig.5). However, it is interesting to note that on MRS the tumour looked like 
a pilocytic astrocytoma but the mIns was low as in patients without NF1 (Cr high as 
in patients with NF1). Furthermore, high mIns has been shown to be an indicator of 
good prognosis and this patient did not respond to treatment. 
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Fig.5 Short TE Single Voxel Spectroscopy of right thalamic Lesion; Voxel 
placement- A= axial view, B= coronal view. C= Spectrum  
Intensity 
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After open image guided biopsy in January 2009, the diagnosis of a low grade 
astrocytoma, likely pilocytic astrocytoma was made. Post-operatively there was an 
intratumoural bleed. Tissue availability for diagnosis was limited, but the diagnosis 
of low grade glioma was sufficiently firm, and no further specimens were needed, 
and resective surgery would present a significant risk. Treatment under the SIOP-
LGG2 protocol (9) was started with chemotherapy (carboplatin and vincristine). 
 
In June 2009 there was worsening left sided weakness and an MRI scan was 
performed. The weakness was attributed mainly to vincristine toxicity. The tumour 
had decreased in size overall, particularly the cystic element, and was thought 
indicative of chemotherapy response. The decision to continue on the reduced 
dose of vincristine he was already on was made. Single voxel MRS (Fig.6) was not 
helpful due to the bleed and the close proximity of the voxel to bone, which 
resulted in a bad quality spectrum.  
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Fig.6 Single voxel MRS June 2009. Voxel placement, A.=sagittal view, B= axial 
view, C=coronal view. D. Uninterpretable spectrum due to intratumoural bleed and 
voxel’s proximity to bone. Ins=myo-inositol, Cho=choline, Cr=creatine, NAA=N-
Acetylaspartate 
 
 
C. D. 
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In August 2009, an MRI scan showed that the residual solid/cystic tumour had 
increased in size by more than 25% in all planes (mainly but not exclusively the 
cystic component), and this was considered to represent disease progression. 
Therapy was changed to vinblastine, and 6 weeks into this treatment the patient 
developed worsening morning headaches and vomiting. MRI in November 2009 
showed marked hydrocephalus related to an increase in size of one of the cystic 
areas of the tumour (size of solid tumour being stable). The hydrocephalus was 
drained and a VP shunt inserted, and treatment continued as there was no 
evidence of failure. MRI in February 2010 showed the cysts to be much smaller 
and the solid component of the tumour slightly larger on the transverse 
measurement. This could have been due to the lack of the prior mass effect from 
the cysts, and the overall size of the solid component was unchanged. Vinblastine 
was continued. Short echo time CSI (Fig.7) with smaller voxels (10mm grid) was 
reassuring, because although some spectra were uninterpretable due to the bleed, 
spectra around the bleed were indicative of pilocytic astrocytoma.  
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Fig.7 Magnetic Resonance Spectroscopic Imaging Study. A. Bad quality spectrum 
due to intratumoural bleed/voxel location near bone. B. Better quality spectrum 
adjacent to the bleed, indicative of a pilocytic astrocytoma.  
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 In July 2010, the patient was stable and well and MRI showed a small (about 
2mm) increase in the size of the enhancing solid tumour with no change in the 
cyst. The decision was to observe and treat when symptoms occur and/or scan 
appearances dictate, as any other treatment would be third line.  
 
In Nov 2010, there was a small increase in size of enhancing tumour, and the 
patient was observed. In January 2011 there was subtle worsening of the left sided 
weakness, and MRI showed a further slight increase in the solid/cystic mass in the 
right thalamus/midbrain. Treatment with chemotherapy (actinomycin and 
vincristine) was started. 
 
8.3. CONCLUSION 
 
The first case has demonstrated the use of MRSI in non-invasively assessing large 
heterogeneous lesions, where areas of different malignancy may be present. The 
second case demonstrated the value of having smaller voxels in MRSI compared 
to SVS, which can be used to assess specific tumour areas, such as around a 
bleed, and aid in the diagnosis of challenging tumours which do not respond to 
treatment.  
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CHAPTER 9 
 
TEXTURE ANALYSIS OF T1- AND T2-WEIGHTED MAGNETIC RESONANCE 
IMAGES AND PROBABILISTIC NEURAL NETWORK TO DISCRIMINATE 
POSTERIOR FOSSA TUMOURS IN CHILDREN 
 
9.1. INTRODUCTION 
 
MRS has been shown to provide additional information for the diagnosis and 
prognosis of paediatric low grade gliomas, and can be performed at the same time 
as conventional MR imaging. Conventional MR imaging is collected on all cases of 
paediatric brain tumours, and is usually assessed qualitatively; quantitative 
analysis is rarely undertaken. However, there is a potential wealth of information 
not visible to the human eye which can be extracted from MR images and 
quantified using texture analysis techniques. This may yield additional information 
to characterize paediatric brain tumours, provide new insights on the characteristic 
features, and enable the combination of MRI and MRS data.  
In this study, texture analysis for the diagnosis of paediatric posterior fossa 
tumours has been employed. Posterior fossa tumours are studied here as they are 
relatively common and usually biopsied, therefore providing a useful test-bed for 
the technique. The commonest posterior fossa tumours are pilocytic astrocytomas 
(grade 1), medulloblastomas (grade 4), and ependymomas (grade 2 or 3) (7). 
Although posterior fossa tumours are generally resected (except those located in 
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the brainstem) (11), having a means of non-invasive diagnosis is useful in guiding 
and planning treatment. Conventionally, radiologists use image patterns and 
associate a diagnosis with these (153).  However, it is to be expected that the 
accuracy of this diagnosis depends on the training, expertise and judgment of the 
radiologist and invariably carries a degree of variability between (and within) 
radiologists (153). Furthermore, radiologists can only use information visible to the 
human eye. Texture analysis can quantify the variation in image patterns, and 
includes data not visible to the human eye (153). It can be particularly valuable 
where robustness is important, such as in monitoring disease progression or the 
longitudinal evaluation of new therapeutic agents (153) and clinical trials 
(especially multicentre). In addition, using information present on the conventional 
MR imaging means that no additional infrastructure, expertise or cost is required, 
and the technique can be widely implemented.  
 
Texture analysis has shown promise in discriminating between lesions on MR 
images (153) and gives quantitative, reproducible results. It has been used in brain 
tumours, epilepsy, multiple sclerosis and other disorders (153-155), as wells as for 
various image types (e.g. MR, X-Ray, camera) (156-163). Texture analysis 
involves four issues: feature extraction, which refers to using a digital image and 
computing a feature that can describe the texture numerically; texture 
discrimination, which involves identifying perceptually homogeneous regions  and 
leads to image segmentation; texture classification, which assigns each 
 156 
 
homogeneous texture region to one of the defined classes; shape from texture, 
which is a reconstruction of 3D surface geometry from texture information (164).  
 
In this study we look at feature extraction and texture classification, to classify 
paediatric brain tumours of the posterior fossa into pilocytic astrocytomas, 
medulloblastomas and ependymomas.  There are many textural features which 
can be investigated and various ways of computationally implementing the 
analysis. One of the methods which has been used in research and is well 
documented in the literature is the MaZda software, a software package for 2D and 
3D image texture analysis (156), and this was used in this study. There are four 
approaches to texture analysis, namely structural, statistical, model based and 
transform methods (164). 279 features can be computed in total.  
 
Another issue in texture analysis is ensuring that the features computed 
characterize the image texture exclusively regardless of the global image 
characteristics, such as overall brightness, contrast, or other bias (156). This is 
achieved in MaZda using a normalization procedure, which reduces the 
dependency of higher-order parameters on first-order gray-level distribution. The 
two image-histogram normalization options are remapping an image histogram in a 
range with the mean luminance in the middle and a range of 3 standard deviations 
onto the white-to-black gray-scale range; or remapping an image histogram in the 
range between the first and 99th percentile onto the white-to-black range (156, 
165). Collewet et al. studied the influence of MRI acquisition protocols (protein-
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density and T2-weighted) and four image intensity normalization methods on 
texture classification of cheese (166). If no normalization or multiplicative 
normalization was performed, the classification errors depended on the MR 
acquisition protocols. This was not the case for the ‘+/-3σ’ normalization, where no 
relationship was found and it provided the best classification results (166). Lerski et 
al.(167) investigated the discrimination between reticulated foam test objects in a 
multicentre trial and found that results from different centers did not agree. 
Although the same MR sequence was used, different scanners (make, model, and 
field strength) were used and no normalization was applied to the images. Also, 
only principal component analysis was used to classify the test objects, and this 
may not have been the most suitable approach (167). Herlidou-Meme et al.(168) 
used data from 3 scanners (T1 and T2 weighted images) on 10 healthy volunteers 
and 63 patients with intracranial tumours, to test the robustness of texture analysis. 
The same statistical textural features were used to segment the tumours, 
irrespective of the acquisition parameters, scanner, reconstruction or processing. 
They found highly reproducible results in a comparison of second-order features 
from T1- and T2-weighted images of gliomas from 3 different MR scanners. 
Importantly, the imaging was carried out at three hospitals using their own routine 
acquisition conditions.  
 
9.1.1 Feature Reduction and Classification 
The general purpose of feature selection is to find the optimum combination of 
features which provides the best classification result. Features which are not 
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relevant to the classification problem should be eliminated. Principal Component 
Analysis is an unsupervised feature reduction technique which is widely used in 
pattern recognition studies (114, 151). 
 
Various types of artificial neural networks (ANNs) have found a widespread use in 
a great number of medical diagnostic decision support system applications 
because of the belief that they are efficient and reliable algorithms with a great 
predictive power as compared to other statistical modeling techniques such as 
statistical regression (169-173). ANNs are highly non-linear computational systems 
capable of modelling complex systems without requiring an explicit knowledge or 
formulation of the relationship existing among the variables. They can be a 
valuable alternative to structured models or empirical correlations between the 
various independent (explanatory) and dependent (response) variables (170, 172, 
174).  The most common neural network, which is the multilayer feed-forward 
network, uses the back-propagation algorithm as a learning rule (171, 173, 175-
178). However, a back-propagation neural network has to be trained for a long time 
to learn the relationship between input and output variables (178).  Moreover, a 
sufficient dataset must be available to divide the data into a training set, a test set 
and a validation set to avoid overfitting (178). Also, the internal behavior of this kind 
of network is not fully understood (176). Probabilistic neural networks (PNN) are an 
alternative method, and they can provide a very general and powerful classification 
model when there is adequate data of known classification. PNN offers several 
advantages over back-propagation networks, such as shorter training time (usually 
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a single pass)(179), effectiveness on small datasets, and easier and better 
interpretability (169, 178, 180).  Moreover, PNN allows true incremental learning 
where new training data can be added at any time without requiring retraining of 
the entire network (178, 181-185).   
 
The PNN operates by defining a probability density function (PDF or kernel 
function) for each data class based on the training set data and an optimized 
kernel spread parameter (σ)(169). The PDF essentially determines the boundaries 
for classification (186). The selection of the value of spread parameter is crucial 
because it determines the width of the basis function that covers the space of the 
input variables. It is also called the “smoothing parameter” (169, 176, 178). 
Different types of radial basis functions could be used, but the most common is the 
multivariate Gaussian function. A large spread has the advantage of producing a 
smooth shape and exhibits good interpolation properties for predicting new pattern 
vectors, however, a large kernel width results in a greater possibility of 
misclassification (169, 176). The optimized kernel width is a compromise between 
an overly small or large σ. An example of a probabilistic neural network is shown in 
Fig. 1 (187). It consists of an input layer, a hidden (or pattern) layer, a summation 
layer and an output layer. 
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Fig.1 Structure of probabilistic neural networks (187) 
 
The training samples are presented to the input layer. In the second, hidden (or 
pattern) layer, there are at least as many neurons as there are training samples. 
The summation layer has as many neurons as classes and there is one output 
layer neuron.  
 
 
9.2. METHODS 
 
9.2.1. Magnetic Resonance Imaging  
Children with pilocytic astrocytomas, medulloblastomas and ependymomas of the 
posterior fossa who had MR imaging at Birmingham Children’s Hospital prior to 
treatment (except stereotactic biopsy) have been included in the study.  
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Acquisition protocol 
Images were acquired on a Siemens Symphony ΜR scanner. T1- weighted (pre-
contrast) axial 2D turbo spin echo (TSE) images were acquired using a TR of 
700ms and a TE of 10-20ms. T2-weighted axial 2D TSE images were acquired 
using a TR of 3000ms and a TE of 100ms. The images were anonymized and 
stored on a research file system at the Institute of Child Health Brain Tumour 
Research Group in DICOM format.  
 
9.2.2. Texture Analysis 
 
T2 images were analyzed first as tumours were generally easier to detect on these, 
and three image slices per patient were chosen, where the tumour was most 
visible/largest and the tumour or region of interest (ROI) was chosen in Image J 
using thresholding +/- manual outlining. This was saved in .bmp format, opened in 
MaZda and saved in .roi format. For T1 images the slices most closely matching 
the T2 slices were used, and the same ROI was used. In MaZda, the image was 
viewed, normalized (using +/- 3σ), the ROI was loaded over it and texture analysis 
run.  
 
9.2.3. Feature Reduction 
 
Principal component analysis (PCA) was applied in Minitab 15, a commercially 
available statistics package, in order to identify the underlying data structure and 
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achieve dimensionality reduction. The number of principal components to be used 
in the classifiers was chosen in order to account for 95% of the cumulative 
variance.  
 
9.2.4. Classification 
 
Classification of the posterior fossa tumours based on the MR image features was 
performed using the principal component scores as input variables in a PNN in 
DTREG v.9.6, a commercially available software. Different PNN training schemes 
can be examined using the commercial software DTREG: (a) a Gaussian kernel or 
a Reciprocal kernel and (b) one smoothing parameter σ for all input random 
variables or a different σ for each input random variable or a separate σ for each 
input random variable and class. A Gaussian kernel and a separate σ for each 
input random variable and class were used as the training scheme, as these gave 
the best results. Also, as the target variable is categorical it is expected that a 
separate σ for each input random variable and class would give better results.   
Smoothing parameters may take values of different orders of magnitude. As these 
parameters have a great effect on the classification performances of PNN, it is 
necessary to automatically assess their optimal values. DTREG uses a conjugate 
gradient method for automatic calculation of the smoothing parameter. To obtain 
the optimal σ, the neural networks with different smoothing parameters were 
trained, the spread varying from 0.0001 to 10 (multiple steps used to find the 
optimal σ, which gives a value for each PC for each class). The PNN had 55 and 
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37 hidden neurons in the second layer for T1 and T2 respectively; these were 
determined using the minimum error criterion, which is one of three criteria which 
can be selected to guide the removal of neurons in DTREG software. There were 
three summation layer neurons; each corresponds to one of three classes and one 
output layer neuron to make a three-class Bayesian decision. Classification errors 
were determined using the known class labels from histopathology. Due to the 
quite small number of data (120 images, 40 patients), the classiﬁer was validated 
using leave-one-out (LOO) cross-validation (leaving one image slice out at a time).  
 
9.3. RESULTS 
 
MR images from 21 patients with medulloblastomas, 14 patients with pilocytic 
astrocytomas and 5 patients with ependymomas were investigated using texture 
analysis.  Principal Component Analysis of texture features from T1-weighted 
images yielded 13 principal components (PC) to explain >95% of the variance. The 
first PC (PC1) mostly represents Co-occurence matrix-derived parameters (Sum 
Entropy) S(1,0)SumEntrp, S(0,1)SumEntrp. PC2 mostly represents Co-occurence 
matrix-derived parameters (Correlation), S(4,0)Correlat, S(3,-3)Correlat, S(2,-
2)Correlat. 
 
These PCs were then used as input to the Probabilistic Neural Network to classify 
the tumours into the three categories (Pilocytic Astrocytoma, Ependymoma, 
Medulloblastoma). The classifier achieved 100% accuracy on training the data and 
 164 
 
93.3% on leave-one-out cross validation (validation data accuracy: 
Medulloblastoma: 98.4%, Ependymoma: 80%, Pilocytic Astrocytoma: 100%).  
 
Principal Component Analysis of texture features from T2-weighted images also 
yielded 13 principal components (PC) to explain >95% of the variance. The first PC 
(PC1) mostly represents Co-occurrence matrix-derived parameters (Difference 
entropy), S(1,-1)DifEntrp, S(2,-2)DifEntrp, S(0,2)DifEntrp. PC2 mostly represents 
Co-occurrence matrix-derived parameters (Sum variance), S(0,2)SumVarnc, 
S(0,1)SumVarnc, S(1,-1)SumVarnc. 
These PCs were then used as input to the Probabilistic Neural Network to classify 
the tumours into the three categories (Pilocytic Astrocytoma, Ependymoma, 
Medulloblastoma). The classifier achieved 100% accuracy on training the data and 
95% on leave-one-out cross validation (Validation data accuracy:  
Medulloblastoma: 100%, Ependymoma: 73.3%, Pilocytic Astrocytoma: 93.2%).  
 
9.4. DISCUSSION 
 
This study shows that texture analysis can be implemented easily on standard T1- 
and T2-weighted images routinely acquired when children present with suspected 
brain tumours of the posterior fossa. The analysis can be done with commercially 
available software, which has extensive manuals to support its use, and therefore 
does not require highly specialized computing knowledge.  In addition, it is possible 
to distinguish between the three commonest paediatric posterior fossa tumours 
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with high accuracy (93.3 and 95% for T1- and T2-weighted images respectively), 
making it a valuable tool to aid diagnosis by contributing information not visible to 
the radiologist on inspection, and also providing a robust method of quantifying the 
images, which can be used where consistency is particularly important.  
 
The features found to hold the highest discriminating potential are all co-
occurrence matrix derived. The co-occurrence matrix is a second-order histogram,  
computed from the intenisites of pairs of pixels. The spatial relationship of the 
pixels in a pair is defined.  When divided by the total number of neighboring pixels 
in the region of interest, this matrix becomes the estimate of the joint probability of 
two pixels, a distance d apart along a given direction θ having particular co-
occurring values i and j. The result is a square matrix with dimensions equal to the 
number of intensity levels in the image, for each distance d and orientation θ (156, 
165).  
 
It is worth noting the classification method used here (PNN), as most of the 
previous studies used some form of linear discriminant analysis (LDA) (153). 
Although this is a reasonable approach and a more straight-forward and perhaps 
more intuitive method, it is important to incorporate and test more advanced 
methods, which may substantially improve classification, as in this study (LDA 
results not shown).    
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Although radiologists are often able to distinguish the type of tumour from 
inspection of the images, this usually includes a degree of uncertainty, and all 3 
tumour types may appear in the differential diagnosis in the radiologists’ report. 
This is because some features can overlap between tumours, and each type of 
tumour can also have variable appearances within the group. For example, 
ependymomas appear isointense to gray matter on T2-weighted images, like 
medulloblastomas. Cerebellar astrocytomas can be low-signal intesnisity on T1-
weighted images, as can ependymomas and medulloblastomas (34, 188). Arle et 
al.(72) studied 33 children with primitive neuroectodermal tumours, astrocytomas 
and ependymomas/other tumours of the posterior fossa with long TE SVS. 
Cr/NAA, NAA/Cho and Cr/Cho, 10 MR imaging tumour characteristics, tumour 
size, patient’s age and sex were used in a neural network and compared to 
predictions made by a neuroradiologist blind to the MRS and histopathology 
results. The neuroradiologist predicted the tumour type with 73% accuracy, and 
neural networks with different data combinations as inputs achieved accuracies of 
58-95%. The neural network which included all data achieved a prediction 
accuracy of 94.6%.   
 
A similar study of paediatric cerebellar tumours by Davies et al.(114) used 
magnetic resonance spectroscopy in the same 3 categories of patients (most 
patients the same as in the study here as performed at BCH) and found an 
accuracy of 94.7% in the glial-cell (astrocytoma+ependymoma) versus non-glial-
cell (medulloblastoma) classifier, 93.1% for astrocytoma vs. medulloblastoma and 
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92.8% for astrocytoma vs. medulloblastomas vs. ependymoma. Principal 
component analysis was used for dimension reduction, and linear discriminant 
analysis for variable selection and classification, with a bootstrap cross-validation 
method (114). It is clearly more difficult to classify 3 groups, but in this study 
comparable accuracies were achieved. It would be interesting to combine the data 
sets to investigate whether there can be any further improvement in classification. 
Posterior fossa tumours are a good test-bed for the technique as they are easier to 
identify on imaging, and they usually belong to one of the 3 categories mentioned. 
Texture analysis and classification could also be applied on other brain tumours, 
such as low grade gliomas, using the analysis scheme described in this paper, and 
the results combined with MRS in the same cohort. In addition, texture analysis 
can be used in prognostication and treatment monitoring to provide additional, 
robust and reproducible information. An important advantage of quantitative 
analysis such as the one presented here, is the ability to combine the results with 
other quantitative techniques such as MRS and diffusion imaging.   
 
9.5. CONCLUSION 
 
This study shows that texture analysis can be implemented easily on standard T1- 
and T2-weighted images routinely acquired when children present with suspected 
brain tumours of the posterior fossa. Discriminatory features do not correspond to 
those used in clinical interpretation of the images and therefore provide novel 
tumour characteristics. This methodology can be extended to other paediatric brain 
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tumours, such as low grade gliomas, and combined with MRS metabolite values in 
a pattern recognition method. Information from the two techniques is likely to be 
independent and the combination could provide improved characterization. The 
analysis can be done with commercially available software, which have extensive 
manuals to support their use, and therefore does not require highly specialized 
computing knowledge. Texture analysis can produce a quantitative analysis of MR 
images which is robust and reproducible, and could play an important role in the 
radiological investigation of patients with brain tumours. 
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CHAPTER 10 
 
CONCLUSIONS AND FUTURE WORK 
 
Multiple aspects of advanced paediatric tumour imaging and biology have been 
studied in this work. Paediatric low grade gliomas present a clinical management 
challenge, but also the need to apply functional imaging techniques to non-
invasively assess them. 1H MRS has been shown to provide diagnostic and 
prognostic information in paediatric brain tumours, but as these are relatively rare, 
there is a need for multicentre studies. Furthermore, most studies have 
investigated various groups of paediatric brain tumours together. Low grade 
gliomas often have a complex clinical course, with multiple recurrences or 
progression, and there is therefore a need for studies to focus on this specific 
group of tumours exclusively.  
 
In this work, the use of 1H MRS in the diagnosis, characterization and 
prognostication of paediatric low grade gliomas is demonstrated; histological 
correlates for metabolites detected by MRS are identified; the ability of in vitro 
NMR to distinguish between cell lines originating from tumours of the same 
histology presenting in different ways is portrayed; applications of chemical shift 
imaging in answering specific clinical questions are demonstrated through case 
studies; and finally another quantitative MR technique, texture analysis, is applied 
to paediatric posterior fossa tumours. This is the first study to the best of our 
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knowledge which investigates an extensive cohort of paediatric low grade gliomas 
with MRS, collecting clinical, imaging and histopathological data from 2 centers 
and 5 scanners, in a robust and reliable manner.  
 
Many important conclusions have been drawn from this work. MRS has been 
shown to detect differences between subgroups of low grade brain tumours in 
children, making MRS a valuable aid to non-invasive diagnosis. Metabolite 
differences between tumours of the same histology have been detected, 
emphasizing the potential for metabolite profiles to improve the characterization of 
these tumours. Investigation of the value of 1H MRS in the prognostication of 
paediatric low grade gliomas revealed high mIns and GPC and low PCh as being 
markers of good prognosis. Furthermore, comparison between sequential MRS 
studies showed that patients with stable disease had lower concentrations of 
metabolites associated with more aggressive tumours in the second MRS 
(compared to the pre-treatment MRS), although this depends on the specific group 
of patients being investigated. Having detected important metabolites in the 
diagnosis and prognostication of paediatric low-grade gliomas, the next step was to 
investigate their correlation to routinely assessed histopathological features. Many 
significant correlations were found, mainly involving choline-containing compounds, 
lipids, taurine, NAA, mIns and Gly. Having investigated in vivo 1H MR spectra and 
detected metabolites of diagnostic and prognostic importance, and also found 
histopathological correlates for many of these, in vitro 1H NMR of different cell lines 
was performed. This demonstrated that 1H NMR has the ability to detect subtle 
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differences and discriminate between three paediatric pilocytic astrocytoma cell 
lines (‘typical’, metastatic and recurrence), and the in vitro spectra demonstrated 
the characteristic features of pilocytic astrocytomas in vivo. Furthermore, no NAA 
was detected in these cell lines in this preliminary work, suggesting that the 
resonance assigned to NAA in in vivo 1H MRS in pilocytic astrocytomas may 
actually correspond to a different molecule, acetate being a possibility. However, 
further work is needed to clarify the origins of NAA seen in vivo in paediatric 
pilocytic astrocytomas. The majority of this work focused on single voxel 
spectroscopy; however, magnetic resonance spectroscopic imaging can also be 
used in the assessment of paediatric brain tumours, and has value in answering 
specific clinical questions, which has been demonstrated through the case studies 
described. Finally, another quantitative technique, texture analysis of MR images, 
has been used to diagnose posterior fossa paediatric brain tumours with high 
accuracy, showing that this can be easily implemented on standard T1- and T2-
weighted images, routinely acquired on all children with a brain tumour.  
 
Although a direct comparison with conventional radiology was not possible in the 
time-frame of this work, the inclusion of MRS in routine MR imaging protocols for 
paediatric brain tumours would enable the collection of larger datasets on these 
relatively rare tumours, thus facilitating future work on the clinical application and 
reliability of the technique. The results presented in this thesis need to be validated 
on larger multicentre datasets, and then prospectively tested in order to provide 
robust evidence for the specific use of MRS in clinical paediatric oncology practice.  
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In addition to the need for validation and testing of the methods and results in this 
work, other questions on MRS in paediatric low grade gliomas have been raised, 
which need to be further explored. In the work on histological correlates of MRS 
metabolites, a larger study using quantitative markers of histological features is 
needed. Conventional MR imaging characteristics could also be tested for their 
histological correlates; for example, T2 intensity can be tested against microcystic 
elements or cell density, and T1 contrast enhancement against vascularity. The 
origins of NAA in paediatric brain tumours in vivo needs to be studied further, as no 
clear answer is available as yet; it is detected reliably in these tumours, cannot be 
attributed to partial volume effects or normal brain infiltration, yet in vitro NMR on 
pilocytic astrocytoma cell lines does not detect any NAA. Cell lines from other low 
grade gliomas need to be grown and tested with in-vitro NMR, to provide better 
characterization of the tumours, or alternatively magic angle spinning on a large 
number of tissue samples performed. Texture analysis needs to be applied on the 
cohort of low grade gliomas presented here and the results combined with 
metabolite values from MRS, to test whether more accurate diagnostic and 
prognostic information can be obtained.  Texture analysis can also be used for 
treatment monitoring in low grade gliomas, as T2 intensity is often seen to 
decrease after treatment. The texture analysis features which are significant 
discriminators between tumours, such as co-occurrence matrix parameters, need 
to be investigated further as to what specifically they represent. A starting point 
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would be to test against the number of blood vessels per image, using CD 34 
staining. 
 
Paediatric low grade gliomas are a challenging condition, both due to their complex 
clinical course and their relatively small numbers which make any clinical study 
difficult to perform. However, they form a very important disease entity, which has 
significant effect on children’s and families’ lives, and continuing efforts to collect 
information on large patient cohorts from multiple centers is crucial. Promising 
results have been reported by our group and others in the field, and advanced 
magnetic resonance imaging techniques now have a significant role in the study of 
these tumours.  
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10.1. Summary of the Main Conclusions  
 MRS can detect differences between subgroups of low grade brain tumours 
in children.  
 The main differences can be readily identified on visual inspection of the 
spectra and quantitative analysis can aid the process of interpretation, 
making MRS a valuable aid to non-invasive diagnosis.  
 The detection of metabolite differences between tumours of the same 
histology emphasizes the potential for metabolite profiles to improve the 
characterization of these tumours and its combination with emerging 
molecular genetic biomarkers should improve the assessment of these 
tumours.  
 High mIns and GPC and low PCh are markers of good prognosis in 
paediatric low grade gliomas. 
 mIns and PCh are significant predictors of survival in a Cox regression 
model.  
 Patients with stable disease show lower metabolite concentrations of lipids+ 
macromolecules, PCh and Ala on their second MRS compared to the pre-
treatment MRS, or no change in metabolites, depending on the treatment 
group. 
 Patients who progressed had higher Gln in their second MRS study. 
 Ki67 has a significant positive correlation with PCh and GPC+PCh detected 
in paediatric brain tumours.  
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 Apoptosis has a significant positive correlation with lipids+macromolecules 
and taurine.  
 Long TE lipids+macromolecules have a significant positive correlation with 
necrosis.  
 Atypia correlates positively with PCh, GPC+PCh and 
lipids+macromolecules.  
 Mitosis correlates positively with PCh and lipids+macromolecules. 
 Lesional neuronal elements correlate negatively with NAA and NAA+NAAG.  
 Neoplastic glial elements correlate positively with mIns, NAA, NAA+NAAG 
and negatively with Gly. 
 GFAP staining correlates negatively with Gly.  
 1H NMR has the ability to detect subtle differences and discriminate 
between three paediatric pilocytic astrocytoma cell lines (‘typical’, metastatic 
and recurrence).  
 The in vitro 1H NMR spectra of the pilocytic astrocytoma cell lines 
demonstrate the characteristic features of pilocytic astrocytomas in vivo.  
 No NAA is detected in these cell lines in this preliminary work, and it is 
suggested that the resonance assigned to NAA in in vivo 1H MRS in 
pilocytic astrocytomas may actually correspond to a different molecule, 
acetate being a possibility. However, further work is needed to clarify the 
origins of NAA seen in vivo in paediatric pilocytic astrocytomas.  
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 MRSI is useful in non-invasively assessing large heterogeneous lesions, 
where areas of different grade may be present.  
 MRSI can be used to assess specific tumour areas, such as around a bleed, 
and aid in the diagnosis of challenging tumours which do not respond to 
treatment.  
 Texture analysis can be implemented easily on standard T1- and T2-
weighted images routinely acquired when children present with suspected 
brain tumours of the posterior fossa and achieves high classification 
accuracies using a PNN.  
 Discriminatory features do not correspond to those used in clinical 
interpretation of the images and therefore provide novel tumour 
characteristics.  
 
Some of the work presented in this thesis has been published in conference 
papers, listed at the beginning of the thesis. 
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APPENDIX 1 DATABASE DESIGN 
 REGISTRATION 
Hospital number_Hospital 
Name 
DOB 
Gender 
Hospital 
Ethnicity 
NF1 
Tuberous Sclerosis 
Date of diagnosis 
Progressed 
Date of progression 
Progression comments 
Date of last known clinical contact 
Date data collected 
Comments 
Alive 
Date of death 
Cause of death 
Cause of death comments 
DIAGNOSIS 
Hospital number_Hospital 
Histological diagnosis performed 
Date of histology 
Consencus diagnosis 
Consencus grade 
Diagnosis comments 
Unusual features 
Final diagnosis to use 
Episode 
Diagnosis id 
OBSERVATION 
Hospital number_Hospital 
Observation 
Date observation started 
Date observation stopped 
Reason for stopping observation 
Observation comments 
Episode 
Observation id 
TREATMENT  
Hospital number_Hospital 
Treatment trial 
Observation 
Surgery 
Chemotherapy 
Radiotherapy 
Diencephalic syndrome 
Focal neurological deficit 
Seizures 
Increased ICP 
Definite history of visual deterioration 
Borderline vision (threat to vision) 
Nystagmus due to visual impairement in infants 
Symptomatic metastases 
Manifestation of new neurologic symptoms secondary to tumour growth 
Increase in severity of existing neurologic symptoms 
Any loss of vision in 2nd eye if the other eye is blind 
Increase in tumour size >25% 
Increase in tumour size 
Increase in cystic part of tumour 
New lesions 
Indication comments 
Episode 
Date of episode 
Treatment id 
SURGERY 
Hospital number_Hospital 
Surgery 
Date of surgery 
Type of surgery 
Post-operative stage- surgical assessment 
Post-operative stage-Radiological assessment 
Surgery comments 
Surgical report needed 
Surgical report read 
Episode 
Surgery id 
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All tables are connected by a one-to-many relationship from the Registration table, 
using Hospital number_Hospital 
MRI 
Hospital number_Hospital 
MRI date 
followup 
Is there an MRS 
Site of tumour 
Side of tumour 
Site of tumour comments 
Disease outside primary 
Number of sites affected 
Which sites 
Stage 
Recurrance outside primary site 
Stage at recurrence 
Recurrence comments 
CSF result checked 
MRI id 
CHEMOTHERAPY 
Hospital number_Hospital 
Chemotherapy 
Date chemotherapy started 
Date chemotherapy completed 
Name of protocol 
Drugs 
Drugs free text 
Chemotherapy comments 
Reason for ending treatment 
Episode 
Chemotherapy id 
RADIOTHERAPY 
Hospital number_Hospital 
Radiotherapy 
Date radiotherapy started 
Date radiotherapy completed 
Comments 
Total dose delivered 
Fraction dose 
Interruptions 
Number of days of interruption 
Reason for ending treatment 
Episode 
Radiotherapy id 
MRS 
ID 
Hospital number_Hospital 
Date of MRS 
Time of MRS 
Pre-treatment 
Scanner 
TE 
Field strength 
Type of MRS 
RDA file 
Processed with LCModel 
Comments for CSI 
Data Missing 
Data missing_comments 
Voxel location 
Voxel location comments 
Quality of MRS_ICH WATER 
Quality of MRS_ICH WEDDY_tick if need to use WEDDY 
Quality of MRS comments 
Possibility of MRS on NBO 
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APPENDIX 2 MATLAB CODES 
MATLAB CODE 1 
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MATLAB CODE 2 
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